Biography
Dr. Neal holds a medical degree and a doctoral degree in Tumor Cell Biology from Northwestern University in Chicago, Illinois. Subsequently, he completed a fellowship in oncology, rotating through the Dana-Farber Cancer Institute and Massachusetts General Hospital in Boston, Massachusetts. He is currently an Associate Professor in the Division of Oncology at the Stanford Cancer Institute at Stanford University in Palo Alto, California. Dr Neal’s primary clinical interest is in thoracic oncology. In addition to maintaining an active practice, he focuses on the design and conduct of clinical trials involving targeted therapies and immunotherapy for lung cancer and mesothelioma. He has published dozens of articles in the field of thoracic oncology, including in Lancet Oncology, Nature Medicine, and the Journal of Clinical Oncology. He is a member of the International Association of the Study of Lung Cancer (IASLC), is a study chair and thoracic core committee member within the ECOG-ACRIN cooperative group, and has presented at a number of American Society of Clinical Oncology (ASCO) annual meetings.
View Full Biography
Professional Summary
Education & Certifications
- Residency: Beth Israel Deaconess Medical Center Internal Medicine Residency (2007) MA
- Medical Education: Northwestern University Feinberg School of Medicine (2004) IL
- Fellowship: Dana Farber Cancer Institute Hematology Oncology Fellowship (2010) MA
-
- Board Certification: American Board of Internal Medicine, Medical Oncology (2010)
Publications
-
Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc
Neal, J. W., & Clipstone, N. A. (2001). Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc. JOURNAL OF BIOLOGICAL CHEMISTRY, 276(5), 3666–3673. -
Calcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 cells
Neal, J. W., & Clipstone, N. A. (2002). Calcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 cells. JOURNAL OF BIOLOGICAL CHEMISTRY, 277(51), 49776–49781. -
A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts
Neal, J. W., & Clipstone, N. A. (2003). A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts. JOURNAL OF BIOLOGICAL CHEMISTRY, 278(19), 17246–17254. -
-
Induction of FucT-VII by the Ras/MAP kinase cascade in Jurkat T cells
Barry, S. M., Zisoulis, D. G., Neal, J. W., Clipstone, N. A., & Kansas, G. S. (2003). Induction of FucT-VII by the Ras/MAP kinase cascade in Jurkat T cells. BLOOD, 102(5), 1771–1778. -
Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.
Neal, J. W., & Sequist, L. V. (2010). Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations. Nature Reviews. Clinical Oncology, 7(2), 71–72. -
Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh
Neal, J. W., & Sequist, L. V. (2010). Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 11(1-2), 36–44. -
AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer
Neal, J., & Wakelee, H. (2010). AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer. CURRENT OPINION IN MOLECULAR THERAPEUTICS, 12(4), 487–95. -
The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer
Neal, J. W. (2010). The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer. FUTURE ONCOLOGY, 6(12), 1827–1832. -
One Allele's Loss Is Another's Gain: Alterations of NKX2-8 in Non-Small Cell Lung Cancer
Neal, J. W., & Shaw, A. T. (2011). One Allele's Loss Is Another's Gain: Alterations of NKX2-8 in Non-Small Cell Lung Cancer. CLINICAL CANCER RESEARCH, 17(4), 638–639. -
Targeting FGFR, Ephrins, Mer, MET, and PDGFR-alpha in Non-small Cell Lung Cancer
Riess, J. W., & Neal, J. W. (2011). Targeting FGFR, Ephrins, Mer, MET, and PDGFR-alpha in Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 6(11), S1797–S1798. -
Current Management of Small Cell Lung Cancer
Neal, J. W., Gubens, M. A., & Wakelee, H. A. (2011). Current Management of Small Cell Lung Cancer. CLINICS IN CHEST MEDICINE, 32(4), 853-? -
Complex Role of Histone Deacetylase Inhibitors in the Treatment of Non-Small-Cell Lung Cancer
Neal, J. W., & Sequist, L. V. (2012). Complex Role of Histone Deacetylase Inhibitors in the Treatment of Non-Small-Cell Lung Cancer. JOURNAL OF CLINICAL ONCOLOGY, 30(18), 2280–2282. -
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Lynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., … Reck, M. (2012). Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study. JOURNAL OF CLINICAL ONCOLOGY, 30(17), 2046–2054. -
A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
Diaz-Padilla, I., Siu, L. L., San Pedro-Salcedo, M., Razak, A. R. A., Colevas, A. D., Shepherd, F. A., … Wakelee, H. A. (2012). A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. BRITISH JOURNAL OF CANCER, 107(4), 604–11. -
A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small-Cell Lung Cancer
Goldberg, S. B., Supko, J. G., Neal, J. W., Muzikansky, A., Digumarthy, S., Fidias, P., … Sequist, L. V. (2012). A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small-Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 7(10), 1602–1608. -
First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors.
Nguyen, K.-S. H., & Neal, J. W. (2012). First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. Biologics : Targets & Therapy, 6, 337–45. -
Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer.
Riess, J. W., & Neal, J. W. (2012). Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer. Journal of Thoracic Oncology , 7(16), S385–6. -
Aflibercept in lung cancer
Neal, J. W., & Wakelee, H. A. (2013). Aflibercept in lung cancer. EXPERT OPINION ON BIOLOGICAL THERAPY, 13(1), 115–20. -
A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab.
Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., & Wakelee, H. A. (2013). A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab. Journal of Thoracic Oncology , 8(2), e17–8. -
A Patient With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib
Riess, J. W., Nagpal, S., Neal, J. W., & Wake, H. A. (2013). A Patient With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(4), 389–94. -
REGULATION OF THE GLUCOSE-H+ SYMPORTER BY METABOLITE-ACTIVATED ATP-DEPENDENT PHOSPHORYLATION OF HPR IN LACTOBACILLUS-BREVIS
Ye, J. J., Neal, J. W., Cui, X. W., Reizer, J., & Saier, M. H. (1994). REGULATION OF THE GLUCOSE-H+ SYMPORTER BY METABOLITE-ACTIVATED ATP-DEPENDENT PHOSPHORYLATION OF HPR IN LACTOBACILLUS-BREVIS. JOURNAL OF BACTERIOLOGY, 176(12), 3484–3492. -
Prolonged Survival in Non-Small Cell Lung Cancer (NSCLC) Patients with Leptomeningeal Metastases (LM) in the Modern Treatment Era
Riess, J. W., Nagpal, S., Iv, M., Zeineh, M., Gubens, M. A., Neal, J. W., & Wakelee, H. A. (2012). Prolonged Survival in Non-Small Cell Lung Cancer (NSCLC) Patients with Leptomeningeal Metastases (LM) in the Modern Treatment Era. JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Cell-free DNA as a Biomarker of Residual Disease Following Radiation Therapy for Non-small Cell Lung Cancer
Bratman, S. V., Eclov, N. C., Modlin, L. A., Neal, J., Loo, B. W., Wu, G., … Diehn, M. (2012). Cell-free DNA as a Biomarker of Residual Disease Following Radiation Therapy for Non-small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S713–S713. -
First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.
Neal, J. W., & Sequist, L. V. (2010). First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations. Clinical Advances in Hematology & Oncology : H&O, 8(2), 119–126. -
Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Neal, J. W., Heist, R. S., Fidias, P., Temel, J. S., Huberman, M., Marcoux, J. P., … Sequist, L. V. (2010). Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. Journal of Thoracic Oncology , 5(11), 1855–1858. -
A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC).
Chen, H., Modiano, M. R., Neal, J. W., Brahmer, J. R., Rigas, J. R., Jotte, R. M., … Wakelee, H. A. (2012). A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 30(15). -
The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
Neal, J. W., Pennell, N. A., Govindan, R., Lanuti, M., Rosovsky, R. P. G., Heist, R. S., … Sequist, L. V. (2012). The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 30(15). -
The Select Study: A Multicenter Phase II Trial Of Adjuvant Erlotinib In Resected Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer (NSCLC)
Neal, J. W., Pennell, N. A., Govindan, R., Heist, R. S., Shaw, A. T., Muzikansky, A., … Sequist, L. V. (2012). The Select Study: A Multicenter Phase II Trial Of Adjuvant Erlotinib In Resected Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer (NSCLC). JOURNAL OF THORACIC ONCOLOGY, 7(9), S209–S209. -
A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements.
Riess, J. W., Padda, S. K., Bangs, C. D., Das, M., Neal, J. W., Adrouny, A. R., … Wakelee, H. A. (2013). A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements. Clinical Lung Cancer, 14(5), 592–95. -
Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips.
Earhart, C. M., Hughes, C. E., Gaster, R. S., Ooi, C. C., Wilson, R. J., Zhou, L. Y., … Wang, S. X. (2013). Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips. Lab on a Chip, 14(1), 78–88. -
Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.
Riess, J. W., Nagpal, S., Iv, M., Zeineh, M., Gubens, M. A., Ramchandran, K., … Wakelee, H. A. (2014). Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. Clinical Lung Cancer, 15(3), 202–6. -
Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips
Earhart, C. M., Hughes, C. E., Gaster, R. S., Ooi, C. C., Wilson, R. J., Zhou, L. Y., … Wang, S. X. (2014). Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips. LAB ON A CHIP, 14(1), 78–88. -
A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.
Chen, H., Modiano, M. R., Neal, J. W., Brahmer, J. R., Rigas, J. R., Jotte, R. M., … Wakelee, H. A. (2014). A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. British Journal of Cancer, 110(3), 602–8. -
Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung.
Cagle, P. T., Sholl, L. M., Lindeman, N. I., Alsabeh, R., Divaris, D. X. G., Foulis, P., … Yu, P. P. (2014). Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung. Archives of Pathology & Laboratory Medicine, 138(2), 171–74. -
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., … Diehn, M. (2014). An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine, 20(5), 548–54. -
Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients.
Riess, J. W., Bhattacharya, N., Blenman, K. R. M., Neal, J. W., Hwang, G., Pultar, P., … Wakelee, H. A. (2014). Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients. Immunopharmacology and Immunotoxicology, 36(2), 182–86. -
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., … Diehn, M. (2014). An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. NATURE MEDICINE, 20(5), 552–58. -
A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab
Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., & Wakelee, H. A. (2013). A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab. JOURNAL OF THORACIC ONCOLOGY, 8(2), E17–E18. -
Review of the current targeted therapies for non-small-cell lung cancer.
Nguyen, K.-S. H., Neal, J. W., & Wakelee, H. (2014). Review of the current targeted therapies for non-small-cell lung cancer. World Journal of Clinical Oncology, 5(4), 576–87. -
Unicentric, multifocal castleman disease of the mediastinum associated with cerebellitis.
Hamaji, M., Neal, J. W., & Burt, B. M. (2015). Unicentric, multifocal castleman disease of the mediastinum associated with cerebellitis. Annals of Thoracic Surgery, 99(1), e7–9. -
Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours.
Neal, J. W., & Sledge, G. W. (2014). Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours. Nature Reviews. Clinical Oncology, 11(11), 627–28. -
Pemetrexed in patients with thymic malignancies previously treated with chemotherapy.
Liang, Y., Padda, S. K., Riess, J. W., West, R. B., Neal, J. W., & Wakelee, H. A. (2015). Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. Lung Cancer , 87(1), 34–38. -
GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray.
Riess, J. W., West, R., Dean, M., Klimowicz, A. C., Neal, J. W., Hoang, C., & Wakelee, H. A. (2015). GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray. Anticancer Research, 35(2), 669–76. -
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
Heist, R. S., Duda, D. G., Sahani, D. V., Ancukiewicz, M., Fidias, P., Sequist, L. V., … Jain, R. K. (2015). Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 112(5), 1547–52. -
Diffuse High Intensity PD-L1 Staining in Thymic Epithelial Tumors.
Padda, S. K., Riess, J. W., Schwartz, E. J., Tian, L., Kohrt, H. E., Neal, J. W., … Wakelee, H. A. (2015). Diffuse High Intensity PD-L1 Staining in Thymic Epithelial Tumors. Journal of Thoracic Oncology , 10(3), 500–508. -
Developing biomarker-specific end points in lung cancer clinical trials
Neal, J. W., Gainor, J. F., & Shaw, A. T. (2015). Developing biomarker-specific end points in lung cancer clinical trials. NATURE REVIEWS CLINICAL ONCOLOGY, 12(3), 135–46. -
Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond.
Neal, J. W., & Sequist, L. V. (2013). Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond. Translational Lung Cancer Research, 2(5), 411–14. -
MET inhibitors in combination with other therapies in non-small cell lung cancer.
Padda, S., Neal, J. W., & Wakelee, H. A. (2012). MET inhibitors in combination with other therapies in non-small cell lung cancer. Translational Lung Cancer Research, 1(4), 238–53. -
Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer
Sequist, L. V., Soria, J.-C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., … Camidge, D. R. (2015). Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 372(18), 1700–1709. -
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
Piotrowska, Z., Niederst, M. J., Karlovich, C. A., Wakelee, H. A., Neal, J. W., Mino-Kenudson, M., … Sequist, L. V. (2015). Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discovery, 5(7), 713–22. -
Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction
Das, M., Padda, S. K., Frymoyer, A., Zhou, L., Riess, J. W., Neal, J. W., & Wakelee, H. A. (2015). Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction. LUNG CANCER, 89(3), 280–86. -
Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non-Small-Cell Lung Cancer
Liang, Y., Wakelee, H. A., & Neal, J. W. (2015). Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non-Small-Cell Lung Cancer. CLINICAL LUNG CANCER, 16(5), 366–73. -
Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
Chuang, J. C., Neal, J. W., Niu, X.-M., & Wakelee, H. A. (2015). Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects. Lung Cancer , 90(1), 1–7. -
Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.
Leung, L.-S. B., Neal, J. W., Wakelee, H. A., Sequist, L. V., & Marmor, M. F. (2015). Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy. American Journal of Ophthalmology, 160(4), 799–805 e1. -
Management of Dermatologic Complications of Lung Cancer Therapies.
Pugliese, S. B., Neal, J. W., & Kwong, B. Y. (2015). Management of Dermatologic Complications of Lung Cancer Therapies. Current Treatment Options in Oncology, 16(10), 50-? -
Pruritus as a Paraneoplastic Symptom of Thymoma
Padda, S. K., Shrager, J. B., Riess, J. W., Pagtama, J. Y., Tisch, A. J. H., Kwong, B. Y., … Wakelee, H. A. (2015). Pruritus as a Paraneoplastic Symptom of Thymoma. JOURNAL OF THORACIC ONCOLOGY, 10(11), E110–E112. -
Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.
Leung, L.-S. B., Neal, J. W., Wakelee, H. A., Sequist, L. V., & Marmor, M. F. (2015). Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy. American Journal of Ophthalmology, 160(4), 799–805 e1. -
Management of Dermatologic Complications of Lung Cancer Therapies.
Pugliese, S. B., Neal, J. W., & Kwong, B. Y. (2015). Management of Dermatologic Complications of Lung Cancer Therapies. Current Treatment Options in Oncology, 16(10), 368-? -
Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene.
Myall, N. J., Neal, J. W., Cho-Phan, C. D., Zhou, L. Y., Stehr, H., Zhou, L., … Wakelee, H. A. (2016). Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene. Clinical Lung Cancer, 17(2), e17–21. -
Outcomes After Combined Modality Therapy for EGFR-Mutant and Wild-Type Locally Advanced NSCLC
Mak, R. H., Doran, E., Muzikansky, A., Kang, J., Neal, J. W., Baldini, E. H., … Sequist, L. V. (2011). Outcomes After Combined Modality Therapy for EGFR-Mutant and Wild-Type Locally Advanced NSCLC. ONCOLOGIST, 16(6), 886–95. -
Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers.
Chuang, J. C., & Neal, J. W. (2015). Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers. Translational Lung Cancer Research, 4(5), 639–41. -
Integrated digital error suppression for improved detection of circulating tumor DNA
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., … Alizadeh, A. A. (2016). Integrated digital error suppression for improved detection of circulating tumor DNA. NATURE BIOTECHNOLOGY, 34(5), 547–55. -
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., … Diehn, M. (2016). Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. NATURE COMMUNICATIONS, 7. -
Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy.
Chuang, J. C., Shrager, J. B., Wakelee, H. A., & Neal, J. W. (2016). Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy. Clinical Therapeutics, 38(7), 1567–76. -
Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction.
Weiskopf, K., Creighton, D., Lew, T., Caswell, J. L., Ouyang, D., Shah, A. T., … Telli, M. L. (2016). Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction. Journal of Oncology Practice / American Society of Clinical Oncology, 12(8), 763–64. -
GLI1, CTNNB1 and NOTCH1 Protein Expression in a Thymic Epithelial Malignancy Tissue Microarray.
Riess, J. W., West, R., Dean, M., Klimowicz, A. C., Neal, J. W., Hoang, C., & Wakelee, H. A. (2015). GLI1, CTNNB1 and NOTCH1 Protein Expression in a Thymic Epithelial Malignancy Tissue Microarray. Anticancer Research, 35(2), 669–76. -
Molecular profiling of single circulating tumor cells from lung cancer patients
Park, S.-M., Wong, D. J., Ooi, C. C., Kurtz, D. M., Vermesh, O., Aalipour, A., … Gambhir, S. S. (2016). Molecular profiling of single circulating tumor cells from lung cancer patients. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 113(52), E8379–E8386. -
PS01.22: Novel 3-Dimensional Preclinical Models: Topic: Medical Oncology.
Salahudeen, A., De La O, S., Padda, S. K., Neal, J. W., Wakelee, H., & Kuo, C. (2016). PS01.22: Novel 3-Dimensional Preclinical Models: Topic: Medical Oncology. Journal of Thoracic Oncology , 11(11S), S282-? -
PS01.04: A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer: Topic: Medical Oncology.
Neal, J. W., Wakelee, H., Padda, S. K., Bertrand, S., Acevedo, B., Holmes Tisch, A., … Nagpal, S. (2016). PS01.04: A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer: Topic: Medical Oncology. Journal of Thoracic Oncology , 11(11S), S271–S272. -
ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
Chuang, J. C., Stehr, H., Liang, Y., Das, M., Huang, J., Diehn, M., … Neal, J. W. (2017). ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. Journal of Thoracic Oncology . -
Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., … Diehn, M. (2016). Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nature Communications, 7, 13513-? -
Elusive Target of Angiogenesis in Small-Cell Lung Cancer.
Neal, J. W., & Wakelee, H. A. (2017). Elusive Target of Angiogenesis in Small-Cell Lung Cancer. Journal of Clinical Oncology , JCO2016716084-? -
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial
Neal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Huang, Y., … Ramalingam, S. S. (2016). Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. LANCET ONCOLOGY, 17(12), 1661–71. -
PS01.67: Case Series of MET Exon 14 Skipping Mutation-Positive Non-Small Cell Lung Cancers and Response to Crizotinib: Topic: Medical Oncology.
Wang, S. X., Zhang, B. M., Wakelee, H., Diehn, M., Kunder, C. A., & Neal, J. W. (2016). PS01.67: Case Series of MET Exon 14 Skipping Mutation-Positive Non-Small Cell Lung Cancers and Response to Crizotinib: Topic: Medical Oncology. Journal of Thoracic Oncology , 11(11S), S312–S313. -
MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC: Topic: Medical Oncology.
Horn, L., Wakelee, H., Reckamp, K. L., Blumenschein, G., Infante, J. R., Carter, C. A., … Lovly, C. M. (2016). MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC: Topic: Medical Oncology. Journal of Thoracic Oncology , 11(11S), S256–S257. -
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
Gautschi, O., Milia, J., Filleron, T., Wolf, J., Carbone, D. P., Owen, D., … Drilon, A. (2017). Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. JOURNAL OF CLINICAL ONCOLOGY, 35(13), 1403-? -
Case Series of MET Exon 14 Skipping Mutation-positive Non-Small Cell Lung Cancers and Response to Crizotinib.
Wang, S. X., Zhang, B., Wakelee, H. A., Diehn, M., Kunder, C., & Neal, J. W. (2017). Case Series of MET Exon 14 Skipping Mutation-positive Non-Small Cell Lung Cancers and Response to Crizotinib. International Journal of Radiation Oncology, Biology, Physics, 98(1), 239-? -
Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer.
Costa, H. A., Neal, J. W., Bustamante, C. D., & Zehnder, J. L. (2017). Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer. Molecular Diagnosis & Therapy. -
Chart Review Versus an Automated Bioinformatic Approach to Assess Real-World Crizotinib Effectiveness in Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer
Bui, N., Henry, S., Wood, D., Wakelee, H. A., & Neal, J. W. (2017). Chart Review Versus an Automated Bioinformatic Approach to Assess Real-World Crizotinib Effectiveness in Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer. JCO: Clinical Cancer Informatics. -
Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.
Choi, C. Y., Wakelee, H. A., Neal, J. W., Pinder-Schenck, M. C., Yu, H.-H. M., Chang, S. D., … Soltys, S. G. (2017). Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial. International Journal of Radiation Oncology, Biology, Physics, 99(1), 16–21. -
Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling.
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., … Diehn, M. (2017). Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discovery. -
Comparison of Circulating Tumor DNA Analysis and Surveillance Imaging After Treatment for Localized Lung Cancer
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A., Stehr, H., Azad, T. D., … Diehn, M. (2017). Comparison of Circulating Tumor DNA Analysis and Surveillance Imaging After Treatment for Localized Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Ultrasensitive Detection of Circulating Tumor DNA in Non-Small Cell Lung Cancer by Deep Sequencing
Diehn, M., Bratman, S. V., Newman, A. M., Neal, J. W., Wakelee, H. A., Merritt, R. E., … Alizadeh, A. (2014). Ultrasensitive Detection of Circulating Tumor DNA in Non-Small Cell Lung Cancer by Deep Sequencing. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Circulating Tumor DNA Analysis during Radiation Therapy for Localized Lung Cancer Predicts Treatment Outcome
Chaudhuri, A. A., Lovejoy, A. F., Chabon, J. J., Newman, A., Stehr, H., Merriott, D. J., … Diehn, M. (2017). Circulating Tumor DNA Analysis during Radiation Therapy for Localized Lung Cancer Predicts Treatment Outcome. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Circulating Tumor DNA Concentrations Reflect Metabolic Tumor Volume in NSCLC
Modlin, L. A., Bratman, S. V., Newman, A. M., Eclov, N. C. W., Neal, J. W., Wakelee, H. A., … Diehn, M. (2014). Circulating Tumor DNA Concentrations Reflect Metabolic Tumor Volume in NSCLC. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
CAPP-Seq Circulating Tumor DNA Analysis for Early Detection of Tumor Progression After Definitive Radiation Therapy for Lung Cancer
Chaudhuri, A. A., Lovejoy, A. F., Chabon, J. J., Newman, A., Stehr, H., Say, C., … Diehn, M. (2016). CAPP-Seq Circulating Tumor DNA Analysis for Early Detection of Tumor Progression After Definitive Radiation Therapy for Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer
Chaudhuri, A., Lovejoy, A., Chabon, J., Newman, A., Stehr, H., Say, C., … Diehn, M. (2017). Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Lung Cancer
Merriott, D. J., Chaudhuri, A. A., Jin, M., Chabon, J. J., Newman, A., Stehr, H., … Diehn, M. (2017). Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Noninvasive and Ultrasensitive Quantitation of Circulating Tumor DNA by Hybrid Capture and Deep Sequencing
Bratman, S. V., Newman, A. M., To, J., Wynne, J. F., Neal, J. W., Wakelee, H., … Diehn, M. (2013). Noninvasive and Ultrasensitive Quantitation of Circulating Tumor DNA by Hybrid Capture and Deep Sequencing. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Mid-radiation Therapy PET/CT for Prognostication and Detection of Early Progression in Patients With Stage III Non-small Cell Lung Cancer
Gensheimer, M. F., Hong, J. C., Chang-Halpenny, C. N., Eclov, N., To, J., Murphy, J. D., … Loo, B. W. (2017). Mid-radiation Therapy PET/CT for Prognostication and Detection of Early Progression in Patients With Stage III Non-small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99(2), E456. -
Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
Gerber, D. E., Socinski, M. A., Neal, J. W., Wakelee, H. A., Shirai, K., Sequist, L. V., … Brahmer, J. R. (2014). Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC). INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90, S36. -
Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer.
Chin, A. L., Kumar, K. A., Guo, H. H., Maxim, P. G., Wakelee, H., Neal, J. W., … Gensheimer, M. F. (2018). Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer. Clinical Lung Cancer. -
ERLOTINIB (E) AND DOVITINIB (TKI258) (D) IN PATIENTS (PTS) WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A SIGNIFICANT PHARMACOKINETIC (PK) INTERACTION
Das, M., Padda, S. K., Zhou, L., Frymoyer, A., Neal, J. W., & Wakelee, H. A. (2013). ERLOTINIB (E) AND DOVITINIB (TKI258) (D) IN PATIENTS (PTS) WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A SIGNIFICANT PHARMACOKINETIC (PK) INTERACTION. JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Programmed death receptor ligand-1 (PD-L1) expression in a thymoma (T) tissue microarray (TMA)
Padda, S. K., Riess, J., Schwartz, E. J., Tian, L., Kohrt, H. E., Neal, J. W., … Wakelee, H. A. (2014). Programmed death receptor ligand-1 (PD-L1) expression in a thymoma (T) tissue microarray (TMA). JOURNAL OF CLINICAL ONCOLOGY, 32(15). -
Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors.
Vaca, S. D., Connolly, I. D., Ho, C., Neal, J., & Hayden Gephart, M. (2017). Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors. Neurosurgery. -
Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?
El-Deiry, W. S., Taylor, B., & Neal, J. W. (2017). Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come? American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Meeting, 37, e8–e15. -
Rociletinib-associated cataracts in EGFR-mutant NSCLC
Piotrowska, Z., Liu, E., Varga, A., Thakur, M., Narayanan, V., Liu, S. V., … Sequist, L. V. (2016). Rociletinib-associated cataracts in EGFR-mutant NSCLC. ANNALS OF ONCOLOGY, 27. -
ENERGY METABOLISM IN LUNG ADENOCARCINOMA
Hoang, C., Xu, Y., Shi, Z., Lin, Y., Merritt, R. E., Shrager, J., … Wakelee, H. A. (2013). ENERGY METABOLISM IN LUNG ADENOCARCINOMA. JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer
Gensheimer, M. F., Hong, J. C., Chang-Halpenny, C., Zhu, H., Eclov, N. C. W., To, J., … Loo, B. W. (2017). Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. RADIOTHERAPY AND ONCOLOGY, 125(2), 338–43. -
The Persistent Promise of Combining HGF/MET and EGFR Inhibition in Non-Small Cell Lung Cancer
Chuang, J. C., & Neal, J. W. (2017). The Persistent Promise of Combining HGF/MET and EGFR Inhibition in Non-Small Cell Lung Cancer. CANCER, 123(15), 2798–2801. -
A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors
Jahchan, N. S., Dudley, J. T., Mazur, P. K., Flores, N., Yang, D., Palmerton, A., … Sage, J. (2014). A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. CANCER RESEARCH, 74(19). -
PEMETREXED IN PATIENTS WITH THYMIC MALIGNANCIES PREVIOUSLY TREATED WITH CHEMOTHERAPY
Liang, Y., Padda, S. K., Riess, J. W., West, R., Neal, J. W., & Wakelee, H. A. (2014). PEMETREXED IN PATIENTS WITH THYMIC MALIGNANCIES PREVIOUSLY TREATED WITH CHEMOTHERAPY. JOURNAL OF THORACIC ONCOLOGY, 9(10), S226. -
STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES
Wakelee, H., Riess, J., Pedro-Salcedo, M. S., Padda, S., Ramchandran, K., Gubens, M., & Neal, J. (2013). STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES. JOURNAL OF THORACIC ONCOLOGY, 8, 22–23. -
CNS activity of ensartinib in ALK1 non-small cell lung cancer (NSCLC) patients (pts)
Reckamp, K. L., Wakelee, H. A., Patel, S., Blumenschein, G., Neal, J. W., Gitlitz, B., … Horn, L. (2017). CNS activity of ensartinib in ALK1 non-small cell lung cancer (NSCLC) patients (pts). ANNALS OF ONCOLOGY, 28. -
PROGRAMMED DEATH RECEPTOR LIGAND-1 (PD-L1) EXPRESSION IN A THYMOMA TISSUE MICROARRAY (TMA)
Padda, S. K., Riess, J. W., Schwartz, E. J., Tian, L., Kohrt, H. E., Neal, J. W., … Wakelee, H. A. (2014). PROGRAMMED DEATH RECEPTOR LIGAND-1 (PD-L1) EXPRESSION IN A THYMOMA TISSUE MICROARRAY (TMA). JOURNAL OF THORACIC ONCOLOGY, 9(10), S212. -
Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose-Escalation Trial
Modlin, L. A., Choi, C. Y. H., Gibbs, I. C., Wakelee, H. A., Neal, J., Pinder-Schenck, M. C., … Soltys, S. G. (2015). Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose-Escalation Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Molecular and Clinicopathologic Features Associated with PD-L1 Expression in Lung Adenocarcinoma
Yang, S., Steiner, D., Berry, G. J., Neal, J. W., Zehnder, J. L., & Kunder, C. A. (2017). Molecular and Clinicopathologic Features Associated with PD-L1 Expression in Lung Adenocarcinoma. JOURNAL OF MOLECULAR DIAGNOSTICS. ELSEVIER SCIENCE INC. -
CORRELATIVE ANALYSIS OF CIRCULATING BIOMARKERS FROM A PHASE 1B/2 TRIAL OF CABOZANTINIB (C) WITH OR WITHOUT ERLOTINIB (E) IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
Padda, S. K., Rosenberg-Hasson, Y., Neal, J. W., Gettinger, S. N., Engelman, J. A., Jaenne, P. A., … Zhou, L. (2013). CORRELATIVE ANALYSIS OF CIRCULATING BIOMARKERS FROM A PHASE 1B/2 TRIAL OF CABOZANTINIB (C) WITH OR WITHOUT ERLOTINIB (E) IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC). JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer
Gerber, D. E., Socinski, M. A., Neal, J. W., Wakelee, H. A., Shirai, K., Sequist, L. V., … Kelly, R. J. (2018). Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. LUNG CANCER, 117, 44–49. -
A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer.
Jahchan, N., Joel, D., Mazur, P., Neal, J., Khatri, P., Butte, A., & Sage, J. (2014). A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer. CLINICAL CANCER RESEARCH, 20. -
Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK plus NSCLC
Horn, L., Wakelee, H., Reckamp, K., Blumenschein, G., Infante, J., Carter, C., … Lovly, C. (2017). Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK plus NSCLC. JOURNAL OF THORACIC ONCOLOGY, 12(1), S1159. -
PRURITUS AS A PARANEOPLASTIC SYMPTOM OF THYMOMA
Padda, S. K., Pagtama, J. Y., Tisch, A. H., Neal, J. W., Riess, J. W., Loo, B. W., … Wakelee, H. A. (2014). PRURITUS AS A PARANEOPLASTIC SYMPTOM OF THYMOMA. JOURNAL OF THORACIC ONCOLOGY, 9(10), S240–S241. -
A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer
Nagpal, S., Wakelee, H., Padda, S., Bertrand, S., Acevedo, B., Tisch, A. H., … Neal, J. (2017). A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
Computed Tomography (CT) Characteristics Associated with the Proposed IASLC/ITMIG TNM Pathologic Staging System for Thymoma
Padda, S. K., Terrone, D., Khuong, A., Tian, L., Neal, J. W., Riess, J. W., … Wakelee, H. A. (2015). Computed Tomography (CT) Characteristics Associated with the Proposed IASLC/ITMIG TNM Pathologic Staging System for Thymoma. JOURNAL OF THORACIC ONCOLOGY, 10(9), S196. -
GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE (AQUA) IN A THYMIC MALIGNANCY TISSUE MICROARRAY (TMA)
Riess, J. W., West, R., Padda, S. K., Dean, M., Klimowicz, A., Huong, C., … Wakelee, H. A. (2013). GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE (AQUA) IN A THYMIC MALIGNANCY TISSUE MICROARRAY (TMA). JOURNAL OF THORACIC ONCOLOGY, 8, S944. -
Case Series of HER2 Mutated Metastatic Lung Adenocarcinoma and Response to HER2 Targeted Therapies
Chuang, J., Neal, J. W., & Wakelee, H. A. (2015). Case Series of HER2 Mutated Metastatic Lung Adenocarcinoma and Response to HER2 Targeted Therapies. JOURNAL OF THORACIC ONCOLOGY, 10(9), S549. -
VeriStrat (R) and Epidermal Growth Factor Receptor Mutation Status in a Phase 1b/2 Study of Cabozantinib plus /- Erlotinib in Non-Small Cell Lung Cancer
Padda, S. K., Lara, P., Gettinger, S. N., Engelman, J. A., Jaenne, P. A., West, H., … Wakelee, H. A. (2015). VeriStrat (R) and Epidermal Growth Factor Receptor Mutation Status in a Phase 1b/2 Study of Cabozantinib plus /- Erlotinib in Non-Small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M.
Sequist, L. V., Soria, J.-C., Gadgeel, S. M., Wakelee, H. A., Camidge, D. R., Varga, A., … Goldman, J. W. (2013). First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M. JOURNAL OF CLINICAL ONCOLOGY, 31(15). -
A Phase lb Study of Erlotinib and Momelotinib for EGFR TKI Naive EGFR Mutated Metastatic Non-Small Cell Lung Cancer
Padda, S., Reckamp, K., Koczywas, M., Neal, J., Brachmann, C., Kawashima, J., … Wakelee, H. (2017). A Phase lb Study of Erlotinib and Momelotinib for EGFR TKI Naive EGFR Mutated Metastatic Non-Small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES
Wakelee, H. A., Riess, J. W., San Pedro-Salcedo, M., Padda, S. K., Ramchandran, K., Gubens, M. A., & Neal, J. W. (2013). STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES. JOURNAL OF THORACIC ONCOLOGY, 8, S731. -
GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE (AQUA) IN A THYMIC MALIGNANCY TISSUE MICROARRAY (TMA)
Riess, J., West, R., Padda, S., Dean, M., Klimowicz, A., Huong, C., … Wakelee, H. (2013). GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE (AQUA) IN A THYMIC MALIGNANCY TISSUE MICROARRAY (TMA). JOURNAL OF THORACIC ONCOLOGY, 8, 25. -
Phase II trial of carboplatin, abraxane, and bevacizumab in NSCLC
Heist, R. S., Duda, G. D., Sahani, D., Ancukiewicz, M., Fidias, P., Sequist, L. V., … Jain, R. K. (2011). Phase II trial of carboplatin, abraxane, and bevacizumab in NSCLC. JOURNAL OF CLINICAL ONCOLOGY, 29(15). -
Phase II Trial of Single Agent Amrubicin in Patients with Previously Treated Advanced Thymic Malignancies
Wakelee, H. A., Padda, S. K., Burns, M., Spittler, A. J., Riess, J. W., San Pedro-Salcedo, M., … Loehrer, P. J. (2015). Phase II Trial of Single Agent Amrubicin in Patients with Previously Treated Advanced Thymic Malignancies. JOURNAL OF THORACIC ONCOLOGY, 10(9), S195. -
A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC)
Neal, J. W., Wakelee, H. A., Feliciano, J. L., Goldberg, S. B., Morgensztern, D., Das, M. S., … Sequist, L. V. (2014). A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 32(15). -
COMPUTED TOMOGRAPHY (CT) CHARACTERISTICS ASSOCIATED WITH MASAOKA-KOGA PATHOLOGIC STAGE IN THYMOMA
Padda, S. K., Terrone, D., Khuong, A., Tian, L., Neal, J. W., Riess, J. W., … Wakelee, H. A. (2014). COMPUTED TOMOGRAPHY (CT) CHARACTERISTICS ASSOCIATED WITH MASAOKA-KOGA PATHOLOGIC STAGE IN THYMOMA. JOURNAL OF THORACIC ONCOLOGY, 9(10), S222. -
FIRST-IN-HUMAN EVALUATION OF CO-1686, AN IRREVERSIBLE, HIGHLY, SELECTIVE TYROSINE KINASE INHIBITOR OF MUTATIONS OF EGFR (ACTIVATING AND T790M)
Soria, J.-C., Sequist, L. V., Gadgeel, S., Goldman, J., Wakelee, H., Varga, A., … Allen, A. (2013). FIRST-IN-HUMAN EVALUATION OF CO-1686, AN IRREVERSIBLE, HIGHLY, SELECTIVE TYROSINE KINASE INHIBITOR OF MUTATIONS OF EGFR (ACTIVATING AND T790M). JOURNAL OF THORACIC ONCOLOGY, 8, S141–S142. -
Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (NSCLC)
Doebele, R., Horn, L., Spira, A., Piotrowska, Z., Costa, D., Neal, J., … Janne, P. (2017). Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (NSCLC). JOURNAL OF THORACIC ONCOLOGY, 12(1), S1072–S1073. -
Outcomes of Moderately Hypofractionated Intensity-Modulated Thoracic Radiotherapy with Concurrent Chemotherapy for Treatment of Non-Small Cell Lung Cancer
Xiang, M., Gensheimer, M. F., Maxim, P. G., Wakelee, H. A., Neal, J. W., Diehn, M., & Loo, B. W. (2017). Outcomes of Moderately Hypofractionated Intensity-Modulated Thoracic Radiotherapy with Concurrent Chemotherapy for Treatment of Non-Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99(2), E504. -
VIETNAMESE NON-SMALL CELL LUNG CANCER PATIENTS IN CALIFORNIA: MOLECULAR PROFILES AND CLINICAL CHARACTERISTICS
Nguyen, K.-S. H., Das, M., Ramchandran, K., Shrager, J., Merritt, R. E., Hoang, C., … Neal, J. W. (2013). VIETNAMESE NON-SMALL CELL LUNG CANCER PATIENTS IN CALIFORNIA: MOLECULAR PROFILES AND CLINICAL CHARACTERISTICS. JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Novel systemic therapy against malignant pleural mesothelioma
Mancuso, M. R., & Neal, J. W. (2017). Novel systemic therapy against malignant pleural mesothelioma. TRANSLATIONAL LUNG CANCER RESEARCH, 6(3), 295–314. -
Noninvasive and ultrasensitive quantitation of circulating tumor DNA by hybrid capture and deep sequencing.
Bratman, S. V., Newman, A. M., To, J., Wynne, J. F., Neal, J. W., Wakelee, H. A., … Alizadeh, A. A. (2014). Noninvasive and ultrasensitive quantitation of circulating tumor DNA by hybrid capture and deep sequencing. JOURNAL OF CLINICAL ONCOLOGY, 32(15). -
A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma
Wakelee, H., Melnikova, V., Karlovich, C., Gadgeel, S., Reckamp, K., Goldman, J. W., … Sequist, L. (2017). A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma. JOURNAL OF THORACIC ONCOLOGY, 12(1), S384–S385. -
Improved survival among lung cancer patients taking antidepressants
Zingone, A., Brown, D., Bowman, E., Vidal, O., Neal, J., Sage, J., & Ryan, B. M. (2015). Improved survival among lung cancer patients taking antidepressants. CANCER RESEARCH, 75. -
Circulating Tumor DNA Detects Residual Disease and Anticipates Tumor Progression Earlier Than CT Imaging
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., … Diehn, M. (2017). Circulating Tumor DNA Detects Residual Disease and Anticipates Tumor Progression Earlier Than CT Imaging. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 98(2), E4. -
PALLIATIVE CARE AND ANTI-CANCER CARE INTEGRATION: DESCRIPTION OF THREE MODELS OF CARE DELIVERY AT A TERTIARY MEDICAL CENTER
Ramchandran, K. J., Fronk, J., Trieu, S., Wakelee, H. A., Das, M., Neal, J. W., … Blayney, D. (2013). PALLIATIVE CARE AND ANTI-CANCER CARE INTEGRATION: DESCRIPTION OF THREE MODELS OF CARE DELIVERY AT A TERTIARY MEDICAL CENTER. JOURNAL OF THORACIC ONCOLOGY, 8, S1324. -
Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial Tumors
Padda, S. K., Terrone, D., Tian, L., Khuong, A., Neal, J. W., Riess, J. W., … Wakelee, H. A. (2018). Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial Tumors. JOURNAL OF THORACIC IMAGING, 33(3), 176–83. -
SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.
Pennell, N. A., Neal, J. W., Chaft, J. E., Azzoli, C. G., Janne, P. A., Govindan, R., … Sequist, L. V. (2014). SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. JOURNAL OF CLINICAL ONCOLOGY, 32(15). -
Cabozantinib (C), erlotinib (E) or the combination (E plus C) as second-or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC): A randomized phase 2 trial of the ECOG-ACRIN Cancer Research Group (E1512).
Neal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Carbone, D. P., & Ramalingam, S. S. (2015). Cabozantinib (C), erlotinib (E) or the combination (E plus C) as second-or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC): A randomized phase 2 trial of the ECOG-ACRIN Cancer Research Group (E1512). JOURNAL OF CLINICAL ONCOLOGY, 33(15). -
A Randomized Phase 2 Trial of Cabozantinib, Erlotinib or the Combination as 2nd or 3rd Line Therapy in EGFR Wild-Type NSCLC: ECOG-ACRIN E1512
Neal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Carbone, D. P., & Ramalingam, S. S. (2015). A Randomized Phase 2 Trial of Cabozantinib, Erlotinib or the Combination as 2nd or 3rd Line Therapy in EGFR Wild-Type NSCLC: ECOG-ACRIN E1512. JOURNAL OF THORACIC ONCOLOGY, 10(9), S373. -
Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM).
Wakelee, H. A., Padda, S. K., Burns, M., Spittler, A. J., Riess, J., San Pedro-Salcedo, M., … Loehrer, P. J. (2015). Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM). JOURNAL OF CLINICAL ONCOLOGY, 33(15). -
Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma
Gao, R. W., Berry, M. F., Kunder, C. A., Khuong, A. A., Wakelee, H., Neal, J. W., … Shrager, J. B. (2017). Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 154(6), 2092-+. -
Phase I/II trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx)
Horn, L., Wakelee, H., Blumenschein, G., Reckamp, K., Waqar, S., Carter, C. A., … Lovly, C. (2016). Phase I/II trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx). ANNALS OF ONCOLOGY, 27. -
Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer
Chaudhuri, A. A., Nabet, B. Y., Merriott, D. J., Jin, M., Chen, E. L., Chabon, J. J., … Diehn, M. (2018). Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Antimicrobial resistance due to antibiotic use for EGFR inhibitor related papulopustular skin reaction
Hirotsu, K., Subramanian, A., Neal, J., Li, S., Pugliese, S., & Kwong, B. (2018). Antimicrobial resistance due to antibiotic use for EGFR inhibitor related papulopustular skin reaction. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 138(5), S176. -
Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer.
Zweig, J. R., & Neal, J. W. (2018). Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2018788554. -
Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
Horn, L., Infante, J. R., Reckamp, K. L., Blumenschein, G. R., Leal, T. A., Waqar, S. N., … Wakelee, H. A. (2018). Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. CLINICAL CANCER RESEARCH, 24(12), 2771–79. -
Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations.
Wang, S. X., Lei, L., Guo, H. H., Shrager, J., Kunder, C. A., & Neal, J. W. (2018). Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations. Lung Cancer (Amsterdam, Netherlands), 122, 187–91. -
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
Brahmer, J. R., Govindan, R., Anders, R. A., Antonia, S. J., Sagorsky, S., Davies, M. J., … Herbst, R. S. (2018). The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). JOURNAL FOR IMMUNOTHERAPY OF CANCER, 6, 75. -
Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study.
Xie, L., Nagpal, S., Wakelee, H. A., Li, G., Soltys, S. G., & Neal, J. W. (2018). Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study. The Oncologist. -
Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small-cell lung cancer.
Sun, T. Y., Niu, X., Chakraborty, A., Neal, J. W., & Wakelee, H. A. (2018). Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. -
Ensartinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients: Updated Data
Leal, T., Wakelee, H., Reckamp, K., Waqar, S., Patel, S., Blumenschein, G., … Horn, L. (2018). Ensartinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients: Updated Data. JOURNAL OF THORACIC ONCOLOGY, 13(9), S156. -
Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam.
Nguyen, K.-S. H., Stehr, H., Zhou, L., Nguyen, A.-H., Hiep, P. N., Van Cau, N., … Neal, J. W. (2018). Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam. Journal of Global Oncology, (4), 1–9. -
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Pennell, N. A., Neal, J. W., Chaft, J. E., Azzoli, C. G., Janne, P. A., Govindan, R., … Sequist, L. V. (2018). SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1800131. -
Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer.
Myall, N. J., Henry, S., Wood, D., Neal, J. W., Han, S. S., Padda, S. K., & Wakelee, H. A. (2018). Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer. Clinical Lung Cancer. -
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
Marcoux, N., Gettinger, S. N., O'Kane, G., Arbour, K. C., Neal, J. W., Husain, H., … Sequist, L. V. (2018). EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1801585. -
Co-Mutations, Natural History, and Outcomes of BRAF-Mutated Non-Small Cell Lung Cancer at a Single Academic Cancer Center
Myall, N., Henry, S., Wood, D., Neal, J., & Wakelee, H. (2018). Co-Mutations, Natural History, and Outcomes of BRAF-Mutated Non-Small Cell Lung Cancer at a Single Academic Cancer Center. JOURNAL OF THORACIC ONCOLOGY, 13(10), S489–S490. -
Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC
Neal, J., Doebele, R., Riely, G., Spira, A., Horn, L., Piotrowska, Z., … Janne, P. (2018). Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC. JOURNAL OF THORACIC ONCOLOGY, 13(10), S599. -
Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
Wang, S. X., Zhang, B. M., Wakelee, H. A., Koontz, M. Z., Pan, M. G., Diehn, M., … Neal, J. W. (2019). Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib. Anti-Cancer Drugs. -
Increased Galectin-1 Expression in Thymic Epithelial Tumors.
Riess, J. W., Kong, C. S., West, R. B., Padda, S. K., Neal, J. W., Wakelee, H. A., & Le, Q.-T. (2018). Increased Galectin-1 Expression in Thymic Epithelial Tumors. Clinical Lung Cancer. -
Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials
Lam, V. K., Hong, D. S., Heymach, J. V., Blumenschein, G., Butler, M. O., Johnson, M., … Amado, R. G. (2018). Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials. ANNALS OF ONCOLOGY, 29. -
Utility of 18F FDG PET/CT in patients with advanced thymic neoplasms
Davidzon, G., Wakelee, H., Neal, J., Mittra, E., Quon, A., & Iagaru, A. (2012). Utility of 18F FDG PET/CT in patients with advanced thymic neoplasms. JOURNAL OF NUCLEAR MEDICINE, 53. -
Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?
El-Deiry, W. S., Taylor, B., & Neal, J. W. (2017). Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come? American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, (37), e8–e15. -
Relationship between anti-depressant use and lung cancer survival.
Zingone, A., Brown, D., Bowman, E. D., Vidal, O., Sage, J., Neal, J., & Ryan, B. M. (2017). Relationship between anti-depressant use and lung cancer survival. Cancer Treatment and Research Communications, 10, 33–39. -
Natural history, treatment (tx) patterns, and outcomes in MET dysregulated non-small cell lung cancer (NSCLC) patients (pts)
Wolf, J., Baik, C., Heist, R. S., Neal, J. W., Mansfield, A. S., Buettner, R., … Awad, M. M. (2018). Natural history, treatment (tx) patterns, and outcomes in MET dysregulated non-small cell lung cancer (NSCLC) patients (pts). EUROPEAN JOURNAL OF CANCER, 103, E131. -
Steroid-Sparing Therapy for Tyrosine Kinase Inhibitor-Induced Pneumonitis
Sun, T. Y., Sung, A. W., & Neal, J. W. (2019). Steroid-Sparing Therapy for Tyrosine Kinase Inhibitor-Induced Pneumonitis. JOURNAL OF THORACIC ONCOLOGY, 14(4), E75–E77. -
Steroid-Sparing Therapy for Tyrosine Kinase Inhibitor-Induced Pneumonitis.
Sun, T. Y., Sung, A. W., & Neal, J. W. (2019). Steroid-Sparing Therapy for Tyrosine Kinase Inhibitor-Induced Pneumonitis. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 14(4), e75–e77. -
Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.
Das, M., Padda, S. K., Frymoyer, A., Zhou, L., Riess, J. W., Neal, J. W., & Wakelee, H. A. (2015). Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction. Lung Cancer (Amsterdam, Netherlands), 89(3), 280–6. -
Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.
Liang, Y., Wakelee, H. A., & Neal, J. W. (2015). Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer. Clinical Lung Cancer, 16(5), 366–73. -
Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor-Related Papulopustular Eruption.
Hirotsu, K., Dang, T. M., Li, S., Neal, J. W., Pugliese, S., Subramanian, A., & Kwong, B. Y. (2019). Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor-Related Papulopustular Eruption. JAMA Dermatology. -
Clinical and Pathological Variables Influencing Noninvasive Detection of Early Stage Lung Cancer Using Circulating Tumor DNA
Chabon, J., Chaudhuri, A., Azad, T., Kurtz, D., Stehr, H., Liu, C. L., … Diehn, M. (2017). Clinical and Pathological Variables Influencing Noninvasive Detection of Early Stage Lung Cancer Using Circulating Tumor DNA. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
A Phase 1b Study of Erlotinib and Momelotinib for TKI-Naive EGFR-Mutated Metastatic Non-Small Cell Lung
Padda, S., Reckamp, K., Koczywas, M., Neal, J., Kawashima, J., Kong, S., … Wakelee, H. (2017). A Phase 1b Study of Erlotinib and Momelotinib for TKI-Naive EGFR-Mutated Metastatic Non-Small Cell Lung. JOURNAL OF THORACIC ONCOLOGY, 12(11), S2142–S2143. -
EGFR Genotyping of Matched Urine, Plasma , and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor
Goldman, J. W., Karlovich, C., Sequist, L., Melnikova, V., Franovic, A., Gadgeel, S. M., … Wakelee, H. A. (2018). EGFR Genotyping of Matched Urine, Plasma , and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor. JCO PRECISION ONCOLOGY, 2, 1–13. -
Response to Ensartinib in TKI Naive ALK plus NSCLC Patients
Wakelee, H., Sanborn, R., Nieva, J., Waqar, S., Brzezniak, C., Bauman, J., … Horn, L. (2017). Response to Ensartinib in TKI Naive ALK plus NSCLC Patients. JOURNAL OF THORACIC ONCOLOGY, 12(11), S1826. -
Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer
Myall, N. J., Henry, S., Wood, D., Neal, J. W., Han, S. S., Padda, S. K., & Wakelee, H. A. (2019). Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer. CLINICAL LUNG CANCER, 20(2), E208–E217. -
Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations
Wang, S. X. Y., Lei, L., Guo, H. H., Shrager, J., Kunder, C. A., & Neal, J. W. (2018). Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations. LUNG CANCER, 122, 187–91. -
Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib
Wang, S. X. Y., Zhang, B. M., Wakelee, H. A., Koontz, M. Z., Pan, M. G., Diehn, M., … Neal, J. W. (2019). Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib. ANTI-CANCER DRUGS, 30(5), 537–41. -
Increased Galectin-1 Expression in Thymic Epithelial Tumors
Riess, J. W., Kong, C. S., West, R. B., Padda, S. K., Neal, J. W., Wakelee, H. A., & Le, Q.-T. (2019). Increased Galectin-1 Expression in Thymic Epithelial Tumors. CLINICAL LUNG CANCER, 20(3), E356–E361. -
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A. B., Mezquita, L., … Gautschi, O. (2019). Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Annals of Oncology : Official Journal of the European Society for Medical Oncology. -
Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer
Chin, A. L., Kumar, K. A., Guo, H. H., Maxim, P. G., Wakelee, H., Neal, J. W., … Gensheimer, M. F. (2018). Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer. CLINICAL LUNG CANCER, 19(5), E581–E588. -
Organoid-based characterization of patient tumors and microenvironments at single cell resolution
Salahudeen, A. A., Zhu, J., Ju, J., Batish, A., Sutha, K., Neal, J. T., … Kuo, C. J. (2018). Organoid-based characterization of patient tumors and microenvironments at single cell resolution. CANCER RESEARCH, 78(13). -
Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.
Aredo, J. V., Padda, S. K., Kunder, C. A., Han, S. S., Neal, J. W., Shrager, J. B., & Wakelee, H. A. (2019). Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes. Lung Cancer (Amsterdam, Netherlands), 133, 144–50. -
Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam
Nguyen, K.-S. H., Stehr, H., Zhou, L., Anh-Hoa Nguyen, Pham Nhu Hiep, Nguyen Van Cau, … Neal, J. W. (2018). Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam. JOURNAL OF GLOBAL ONCOLOGY, 4. -
Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer
Sun, T. Y., Niu, X., Chakraborty, A., Neal, J. W., & Wakelee, H. A. (2019). Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 14(2), E21–E24. -
Review of the current targeted therapies for non-small-cell lung cancer
Nguyen, K.-S. H., Neal, J. W., & Wakelee, H. (2014). Review of the current targeted therapies for non-small-cell lung cancer. WORLD JOURNAL OF CLINICAL ONCOLOGY, 5(4), 576–87. -
MET inhibitors in combination with other therapies in non-small cell lung cancer
Padda, S., Neal, J. W., & Wakelee, H. A. (2012). MET inhibitors in combination with other therapies in non-small cell lung cancer. TRANSLATIONAL LUNG CANCER RESEARCH, 1(4), 238–53. -
Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study
Xie, L., Nagpal, S., Wakelee, H. A., Li, G., Soltys, S. G., & Neal, J. W. (2019). Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study. ONCOLOGIST, 24(6), 836–43. -
Plasma genotyping of patients enrolled on the expansion phase VII trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC).
Horn, L., Wakelee, H. A., Reckamp, K. L., Blumenschein, G. R., Infante, J. R., Carter, C. A., … Lovly, C. M. (2016). Plasma genotyping of patients enrolled on the expansion phase VII trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 34(15). -
Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib.
Chabon, J. ., Simmons, A., Newman, A. M., Lovejoy, A. F., Esfahani, M. S., Haringsma, H., … Diehn, M. (2016). Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib. JOURNAL OF CLINICAL ONCOLOGY, 34(15). -
Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer
Zweig, J. R., & Neal, J. W. (2018). Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer. JOURNAL OF CLINICAL ONCOLOGY, 36(26), 2677-+. -
Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors
Vaca, S. D., Connolly, I. D., Ho, C., Neal, J., & Gephart, M. H. (2018). Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors. NEUROSURGERY, 82(1), E6–E14. -
Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond
Neal, J. W., & Sequist, L. V. (2013). Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond. TRANSLATIONAL LUNG CANCER RESEARCH, 2(5), 411–14. -
First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
Nguyen, K.-S. H., & Neal, J. W. (2012). First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. BIOLOGICS-TARGETS & THERAPY, 6, 337–45. -
Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.
Hellyer, J. A., Stehr, H., Das, M., Padda, S. K., Ramchandran, K., Neal, J. W., … Wakelee, H. A. (2019). Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands), 134, 42–45. -
Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib.
Wakelee, H. A., Gadgeel, S. M., Goldman, J. W., Reckamp, K. L., Karlovich, C. A., Melnikova, V., … Sequist, L. V. (2016). Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib. JOURNAL OF CLINICAL ONCOLOGY, 34(15). -
Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC.
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., … Diehn, M. (2016). Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes".
Aredo, J. V., Padda, S. K., Kunder, C. A., Han, S. S., Neal, J. W., Shrager, J. B., & Wakelee, H. A. (2019). Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes". Lung Cancer (Amsterdam, Netherlands). -
Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor-Related Papulopustular Eruption
Hirotsu, K., Dang, T. M., Li, S., Neal, J. W., Pugliese, S., Subramanian, A., & Kwong, B. Y. (2019). Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor-Related Papulopustular Eruption. JAMA DERMATOLOGY, 155(7), 848–50. -
Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients.
Jeong, Y., Hellyer, J. A., Stehr, H., Hoang, N. T., Niu, X., Das, M., … Diehn, M. (2019). Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies.
Hellyer, J. A., Gubens, M. A., Cunanan, K. M., Padda, S. K., Burns, M., Spittler, A. J., … Loehrer, P. J. (2019). Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies. Lung Cancer (Amsterdam, Netherlands), 137, 71–75. -
ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer.
Moding, E. J., Liu, Y., Nabet, B., Chabon, J. J., Chaudhuri, A., Hui, A. B., … Diehn, M. (2019). ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis.
Neal, J. W., Hausrath, D., Wakelee, H. A., Cunanan, K., Liu, S. V., Banwait, M., … Piotrowska, Z. (2019). Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis. JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.
Chaft, J. E., Costa, D. B., Muzikansky, A., Shrager, J. B., Lanuti, M., Huang, J., … Neal, J. W. (2019). Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC. JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.
Janne, P. A., Neal, J. W., Camidge, D. R., Spira, A. I., Piotrowska, Z., Horn, L., … Riely, G. J. (2019). Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
Characterization of circulating tumor cells and its PD-L1 expression with high-sensitivity liquid biopsy panel in non-small cell lung cancer patients
Liu, X., Ao, Z., Preiss, J. S., Neal, J., Zhou, L. Y., Sambucetti, L., & Wakelee, H. A. (2019). Characterization of circulating tumor cells and its PD-L1 expression with high-sensitivity liquid biopsy panel in non-small cell lung cancer patients. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
A Phase Ib/IIa randomized pilot study to investigate the safety and tolerability of autologous T-cells with enhanced T-cell receptors specific to NY-ESO-1/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer
Reckamp, K. L., Akerley, W., Edelman, M. J., Halmos, B., He, K., Johnson, M., … Lam, V. (2019). A Phase Ib/IIa randomized pilot study to investigate the safety and tolerability of autologous T-cells with enhanced T-cell receptors specific to NY-ESO-1/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer. CANCER RESEARCH, 79(13). -
Clinical and molecular characteristics of responders versus non-responders to immune checkpoint inhibitors (ICI) in NSCLC.
Shah, A., Padda, S. K., & Neal, J. W. (2019). Clinical and molecular characteristics of responders versus non-responders to immune checkpoint inhibitors (ICI) in NSCLC. JOURNAL OF CLINICAL ONCOLOGY, 37(8). -
Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions
Jaenne, P., Neal, J. W., Camidge, D. R., Spira, A., Piotrowska, Z., Horn, L., … Riely, G. J. (2019). Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions. ANNALS OF ONCOLOGY, 30. -
Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK plus ) Non-Small Cell Lung Cancer Patients Treated with Ensartinib
Wakelee, H., Reckamp, K., Leal, T., Chiappori, A., Waqar, S., Zeman, K., … Horn, L. (2019). Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK plus ) Non-Small Cell Lung Cancer Patients Treated with Ensartinib. JOURNAL OF THORACIC ONCOLOGY, 14(10), S566. -
STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC
Skoulidis, F., Arbour, K., Hellmann, M., Patil, P., Marmarelis, M., Owen, D., … Heymach, J. (2019). STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC. JOURNAL OF THORACIC ONCOLOGY, 14(10), S294–S295. -
A Single-Cell Resolution Map of EMT and Drug Resistance States for Evaluating NSCLC Clinical Specimens
Karacosta, L., Anchang, B., Ignatiadis, N., Kimmey, S., Benson, J., Shrager, J., … Plevritis, S. (2019). A Single-Cell Resolution Map of EMT and Drug Resistance States for Evaluating NSCLC Clinical Specimens. JOURNAL OF THORACIC ONCOLOGY, 14(10), S226–S227. -
The Real-World Risk of Brain Metastases in Stage 3 Lung Cancer Patients in the Era of PET and MRI Staging
Ko, R., Therkelsen, K., Von Eyben, R., Neal, J., Loo, B., & Nagpal, S. (2019). The Real-World Risk of Brain Metastases in Stage 3 Lung Cancer Patients in the Era of PET and MRI Staging. JOURNAL OF THORACIC ONCOLOGY, 14(10), S585–S586. -
Antitumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in NSCLC with EGFR Exon 20 Insertions
Riely, G., Neal, J., Camidge, D. R., Spira, A., Piotrowska, Z., Horn, L., … Janne, P. (2019). Antitumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in NSCLC with EGFR Exon 20 Insertions. JOURNAL OF THORACIC ONCOLOGY, 14(10), S412–S413. -
Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study
Reckamp, K. L., Akerley, W., Calvo, E., Clarke, J., Edelman, M. J., He, K., … Johnson, M. L. (2019). Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study. ANNALS OF ONCOLOGY, 30, 657-+. -
Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2)
Leal, T., Wakelee, H., Reckamp, K. L., Chiappori, A., Oxnard, G. R., Waqar, S. N., … Horn, L. (2019). Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2). JOURNAL OF THORACIC ONCOLOGY, 14(11), S1171–S1172. -
Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC.
Hellmann, M. D., Nabet, B. Y., Rizvi, H., Chaudhuri, A. A., Wells, D. K., Dunphy, M. P., … Diehn, M. (2020). Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials.
Lam, V. K., Hong, D. S., Heymach, J. V., Blumenschein, G., Butler, M. O., Johnson, M., … Amado, R. G. (2018). Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 29 Suppl 8, viii731. -
Integrating genomic features for non-invasive early lung cancer detection
Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., … Diehn, M. (2020). Integrating genomic features for non-invasive early lung cancer detection. NATURE. -
Feasibility and design of a cloud-based digital platform in patients with advanced cancer.
Roy, M., Hall, E. T., Velazquez, B., Shah, S., Fardeen, T., Cunanan, K., … Ramchandran, K. (2019). Feasibility and design of a cloud-based digital platform in patients with advanced cancer. JOURNAL OF CLINICAL ONCOLOGY, 37(27). -
Integrating genomic features for non-invasive early lung cancer detection.
Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., … Diehn, M. (2020). Integrating genomic features for non-invasive early lung cancer detection. Nature, 580(7802), 245–251. -
Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).
Mazieres, J., Drilon, A. E., Mhanna, L., Milia, J., Lusque, A., Cortot, A. B., … Gautschi, O. (2018). Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget). JOURNAL OF CLINICAL ONCOLOGY, 36(15). -
Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer
Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., … Diehn, M. (2020). Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. NATURE CANCER, 1. -
A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS.
Riess, J. W., Jahchan, N. S., Das, M., Zach Koontz, M., Kunz, P. L., Wakelee, H. A., … Neal, J. W. (2020). A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS. Cancer Treatment and Research Communications, 23, 100174. -
Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC).
Marcoux, N., Gettinger, S. N., O'Kane, G. M., Arbour, K. C., Neal, J. W., Husain, H., … Sequist, L. V. (2018). Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC). JOURNAL OF CLINICAL ONCOLOGY, 36(15). -
Facile single cell profiling and clonotype analysis of NSCLC immune microenvironments.
Salahudeen, A. A., Zhu, J., Ju, J., Giangarra, V., Montesclaros, L., Sapida, J., … Kuo, C. J. (2018). Facile single cell profiling and clonotype analysis of NSCLC immune microenvironments. JOURNAL OF CLINICAL ONCOLOGY, 36(15). -
PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review.
Zhou, M., Joshi, N., Raj, K. P., Wakelee, H., & Neal, J. W. (2020). PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review. Clinical Lung Cancer. -
First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non-small cell lung cancer (NSCLC).
Doebele, R. C., Riely, G. J., Spira, A. I., Horn, L., Piotrowska, Z., Costa, D. B., … Janne, P. A. (2018). First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 36(15). -
Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure.
Waliany, S., Lee, D., Witteles, R. M., Neal, J. W., Nguyen, P., Davis, M. M., … Zhu, H. (2020). Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure. Annual Review of Pharmacology and Toxicology. -
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.
Nabet, B. Y., Esfahani, M. S., Moding, E. J., Hamilton, E. G., Chabon, J. J., Rizvi, H., … Diehn, M. (2020). Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell. -
KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer.
Binkley, M. S., Jeon, Y.-J., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D. S., … Diehn, M. (2020). KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Discovery of a novel shared tumor antigen in human lung cancer.
Tseng, D., Chiou, S.-H., Yang, X., Reuben, A., Wilhelmy, J., McSween, A., … Davis, M. (2020). Discovery of a novel shared tumor antigen in human lung cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction.
Moding, E. J., Esfahani, M. S., Nabet, B., Liu, Y., Chabon, J. J., He, J., … Diehn, M. (2020). A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Distress screening through PROMIS at an academic cancer center and network site: Implementation of a hybrid model.
Roy, M., Neal, J. W., Bugos, K., Sharp, C., Falconer, P., Rosenthal, E. L., … Ramchandran, K. (2020). Distress screening through PROMIS at an academic cancer center and network site: Implementation of a hybrid model. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.
Ji, J., Aredo, J., Piper-Vallillo, A., Huppert, L., Rotow, J. K., Husain, H., … Riess, J. W. (2020). Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
High-dose osimertinib for CNS progression in EGFR plus non-small cell lung cancer (NSCLC): A multi-institutional experience.
Piper-Vallillo, A., Rotow, J. K., Aredo, J., Shaverdashvili, K., Luo, J., Carlisle, J. W., … Piotrowska, Z. (2020). High-dose osimertinib for CNS progression in EGFR plus non-small cell lung cancer (NSCLC): A multi-institutional experience. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions.
Horn, L., Lin, H. M., Padda, S. K., Aggarwal, C., McCoach, C. E., Zhu, Y., … Neal, J. W. (2020). Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions. JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study.
Neal, J. W., Lim, F. L., Felip, E., Gentzler, R. D., Patel, S. B., Baranda, J., … Ponce Aix, S. (2020). Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study. JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition.
Binkley, M. S., Jeon, Y.-J. J., Nesselbush, M., Moding, E. J., Nabet, B. Y., Almanza, D., … Diehn, M. (2020). KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition. Cancer Discovery. -
Updated results from a phase I/II study of mobocertinib (TAK788) in NSCLC with EGFR exon 20 insertions (exon20ins)
Riely, G. J., Neal, J. W., Camidge, D. R., Spira, A., Piotrowska, Z., Horn, L., … Janne, P. A. (2020). Updated results from a phase I/II study of mobocertinib (TAK788) in NSCLC with EGFR exon 20 insertions (exon20ins). ANNALS OF ONCOLOGY, 31, S815–S816. -
Comparison of clinical outcomes of patients with METDex14 NSCLC treated with first-line capmatinib in the GEOMETRY mono-1 study with those of a cohort of real-world patients
Wolf, J., Neal, J. W., Mansfield, A. S., Doban, V., Kanakamedala, H., Wu, W.-H., … Baik, C. S. (2020). Comparison of clinical outcomes of patients with METDex14 NSCLC treated with first-line capmatinib in the GEOMETRY mono-1 study with those of a cohort of real-world patients. ANNALS OF ONCOLOGY, 31, S863. -
Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC)
Mazieres, J., Tomasini, P., Lusque, A., Boucekine, M., Gautschi, O., Cortot, A. B., … Barlesi, F. (2020). Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC). ANNALS OF ONCOLOGY, 31, S826–S827. -
Three-dimensional organoid model for acquired drug resistance in non-small cell lung cancer
Shukla, N. D., Salahudeen, A. A., Padda, S. K., Neal, J. W., Wakelee, H. A., & Kuo, C. J. (2018). Three-dimensional organoid model for acquired drug resistance in non-small cell lung cancer. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Opportunistic Invasive Fungal Infections Mimicking Progression of Non-Small-Cell Lung Cancer.
Park, M., Ho, D. Y., Wakelee, H. A., & Neal, J. W. (2020). Opportunistic Invasive Fungal Infections Mimicking Progression of Non-Small-Cell Lung Cancer. Clinical Lung Cancer. -
Relative Impact of Anticancer Therapy on Unplanned Hospital Care in Patients With Non-Small-Cell Lung Cancer.
Shah, M. P., & Neal, J. W. (2020). Relative Impact of Anticancer Therapy on Unplanned Hospital Care in Patients With Non-Small-Cell Lung Cancer. JCO Oncology Practice, OP2000612. -
Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring.
Nesvet, J. C., Antilla, K. A., Pancirer, D. S., Lozano, A. X., Preiss, J. S., Ma, W., … Wang, S. X. (2021). Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring. Clinical Chemistry. -
Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
Zhang, M., Rodrigues, A. J., Pollom, E. L., Gibbs, I. C., Soltys, S. G., Hancock, S. L., … Li, G. (2021). Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases. Journal of Neuro-Oncology. -
Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis
Zhu, H., Lee, D., Sarah, W., Galdos, F. X., D'Addabbo, J., Fowler, M. B., … Wu, S. M. (2020). Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis. CIRCULATION RESEARCH. LIPPINCOTT WILLIAMS & WILKINS. -
Brief Report: Role of Consolidation Durvalumab in patients with EGFR and HER2 Mutant Unresectable Stage III NSCLC.
Hellyer, J. A., Aredo, J. V., Das, M., Ramchandran, K., Padda, S. K., Neal, J. W., & Wakelee, H. A. (2021). Brief Report: Role of Consolidation Durvalumab in patients with EGFR and HER2 Mutant Unresectable Stage III NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. -
Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy
Aredo, J. V., Hellyer, J. A., Neal, J. W., Padda, S. K., McCoach, C. E., Riess, J. W., … Wakelee, H. A. (2021). Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy. JOURNAL OF THORACIC ONCOLOGY, 16(1), S15. -
Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy.
Aredo, J. V., Mambetsariev, I., Hellyer, J. A., Amini, A., Neal, J. W., Padda, S. K., … Wakelee, H. A. (2021). Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. -
Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.
White, M. N., Piotrowska, Z., Stirling, K., Liu, S. V., Banwait, M. K., Cunanan, K., … Neal, J. W. (2021). Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression. Clinical Lung Cancer. -
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial.
Riely, G. J., Neal, J. W., Camidge, D. R., Spira, A. I., Piotrowska, Z., Costa, D. B., … Janne, P. A. (2021). Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial. Cancer Discovery. -
A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer
Nabet, B. Y., Esfahani, M. S., Hamilton, E. G., Chabon, J. J., Moding, E. J., Rizvi, H., … Diehn, M. (2020). A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC).
Skoulidis, F., Neal, J. W., Akerley, W. L., Paik, P. K., Papagiannakopoulos, T., Reckamp, K. L., … Rizvi, N. A. (2020). A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC). JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery.
Chiou, S.-H. H., Tseng, D., Reuben, A., Mallajosyula, V., Molina, I. S., Conley, S., … Davis, M. M. (2021). Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. Immunity, 54(3), 586–602.e8. -
Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.
Waliany, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., … Zhu, H. (2021). Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors. JACC. CardioOncology, 3(1), 137–39. -
Distress Screening Through Patient-Reported Outcomes Measurement Information System (PROMIS) at an Academic Cancer Center and Network Site: Implementation of a Hybrid Model.
Neal, J. W., Roy, M., Bugos, K., Sharp, C., Galatin, P. S., Falconer, P., … Ramchandran, K. (2021). Distress Screening Through Patient-Reported Outcomes Measurement Information System (PROMIS) at an Academic Cancer Center and Network Site: Implementation of a Hybrid Model. JCO Oncology Practice, OP2000473. -
Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib
White, M., Neal, J. W., Gardner, R. M., Cunanan, K. M., Das, M., Padda, S. K., … Wakelee, H. (2021). Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib. JOURNAL OF THORACIC ONCOLOGY, 16(4), S773–S774. -
LUNGMAP Master Protocol (LUNGMAP): Concordance Between Plasma ctDNA and Tissue Molecular Analysis
Mack, P., Minichielle, K., Redman, M., Tolba, K., Kozono, D., Waqar, S., … Herbst, R. (2021). LUNGMAP Master Protocol (LUNGMAP): Concordance Between Plasma ctDNA and Tissue Molecular Analysis. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
Healthcare Utilization with an Electronic Patient Reported Outcome (ePRO) tool for Symptom Management in Thoracic Cancers
Roy, M., Fardeen, T., Generalova, O., Hall, E., Cunanan, K., Das, M., … Ramchandran, K. (2021). Healthcare Utilization with an Electronic Patient Reported Outcome (ePRO) tool for Symptom Management in Thoracic Cancers. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A
Hirsch, F., Hua, X., Wu, M., Neal, J., Cheng, H., Gettinger, S., … Kozono, D. (2021). Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma
Aredo, J., Wakelee, H. A., Neal, J., & Padda, S. (2021). Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
Afatinib and Necitumumab in EGFR mutant NSCLC with Acquired Resistance to 1st or 3rd Generation EGFR Tyrosine Kinase Inhibitors
Padda, S., Whisenant, J., Neal, J., York, S., Iams, W., Neuss, M., … Horn, L. (2021). Afatinib and Necitumumab in EGFR mutant NSCLC with Acquired Resistance to 1st or 3rd Generation EGFR Tyrosine Kinase Inhibitors. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis: Secondary Analysis of NLST
Su, C. C., Wu, J., Neal, J., Popat, R., Backhus, L., Leung, A., … Han, S. (2021). Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis: Secondary Analysis of NLST. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI Era
Remon, J., Lacas, B., Herbst, R., Reck, M., Garon, E., Scagliotti, G., … Besse, B. (2021). ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI Era. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
Cabozantinib Plus Atezolizumab in NSCLC Patients Previously Treated with a Checkpoint Inhibitor: Results from COSMIC 021
Neal, J., Lim, F., Felip, E., Gentzler, R., Patel, S., Baranda, J., … Ponce Aix, S. (2021). Cabozantinib Plus Atezolizumab in NSCLC Patients Previously Treated with a Checkpoint Inhibitor: Results from COSMIC 021. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer
Padda, S. K., Aredo, J., Vali, S., Singh, N. K., Vasista, S. M., Kumar, A., … Wakelee, H. A. (2021). Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer. JCO PRECISION ONCOLOGY, 5, 153–62. -
Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer
Neal, J. W., Costa, D. B., Muzikansky, A., Shrager, J. B., Lanuti, M., Huang, J., … Chaft, J. E. (2021). Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer. JCO PRECISION ONCOLOGY, 5, 325–32. -
Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer.
Binkley, M. S., Jeon, Y.-J., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D., … Diehn, M. (2021). Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Circulating tumor DNA kinetics to identify genomic predictors of rapid response to chemoradiation in non-small cell lung cancer.
Moding, E. J., Liu, Y., Hui, A. B., He, J., Qiao, Y., Xu, T., … Diehn, M. (2021). Circulating tumor DNA kinetics to identify genomic predictors of rapid response to chemoradiation in non-small cell lung cancer. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis.
Su, C. C., Wu, J. T., Neal, J. W., Popat, R. A., Kurian, A. W., Backhus, L. M., … Han, S. S. (2021). Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. -
EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.
Shah, M. P., Aredo, J. V., Padda, S. K., Ramchandran, K. J., Wakelee, H. A., Das, M. S., & Neal, J. W. (2021). EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy. Clinical Lung Cancer. -
The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer
Ellis-Caleo, T., & Neal, J. W. (2021). The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer. JOURNAL OF THORACIC DISEASE. -
Radiological tumour classification across imaging modality and histology
Wu, J., Li, C., Gensheimer, M., Padda, S., Kato, F., Shirato, H., … Li, R. (2021). Radiological tumour classification across imaging modality and histology. NATURE MACHINE INTELLIGENCE. -
Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma.
Waliany, S., Zhu, H., Wakelee, H., Padda, S. K., Das, M., Ramchandran, K., … Neal, J. W. (2021). Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. -
Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer.
Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., … Diehn, M. (2020). Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer. Nature Cancer, 1(2), 176–183. -
Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer.
Generalova, O., Roy, M., Hall, E., Shah, S. A., Cunanan, K., Fardeen, T., … Ramchandran, K. (2021). Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer. Journal of Patient-Reported Outcomes, 5(1), 91. -
Immune Checkpoint Inhibitor Pneumonitis: Heterogeneity in Clinical Management
Filsoof, D., Padda, S. K., Garcia, P., Stedman, M., Neal, J. W., Wakelee, H. A., … Katsumoto, T. R. (2021). Immune Checkpoint Inhibitor Pneumonitis: Heterogeneity in Clinical Management. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. AMER THORACIC SOC. -
Pragmatic Application of Computed Tomography Lung Texture Analysis in Immune Checkpoint Inhibitor Pneumonitis: An Exploratory Study
Filsoof, D., Im, J., Garcia, P., Stedman, M., Anand, S., Neal, J. W., … Raj, R. (2021). Pragmatic Application of Computed Tomography Lung Texture Analysis in Immune Checkpoint Inhibitor Pneumonitis: An Exploratory Study. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. AMER THORACIC SOC. -
The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer.
Ellis-Caleo, T., & Neal, J. W. (2021). The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer. Journal of Thoracic Disease, 13(8), 4864–4871. -
Indirect comparison of mobocertinib and standard of care in platinum-pretreated patients with NSCLC with EGFR exon 20 insertion
Ou, S.-H. I., Lin, H. M., Hong, J.-L., Yin, Y., Jin, S., Lin, J., … Neal, J. W. (2021). Indirect comparison of mobocertinib and standard of care in platinum-pretreated patients with NSCLC with EGFR exon 20 insertion. ANNALS OF ONCOLOGY. ELSEVIER. -
Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer.
Devine, M., Merriott, D. J., Say, C., Yoo, C., Yi, E., Lau, B., … Vitzthum, L. (2021). Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 111(3S), e435. -
A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR).
Gensheimer, M. F., Gee, H. E., Von Eyben, R., Shirato, H., Taguchi, H., Wong, S., … Diehn, M. (2021). A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR). International Journal of Radiation Oncology, Biology, Physics, 111(3S), S89–S90. -
Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer
Gupta, D., Fardeen, T., Teuteberg, W., Seevaratnam, B., Asuncion, M. K., Alves, N., … Ramchandran, K. (2021). Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
A Predictive Model to Guide Brain MRI Surveillance in Patients With Metastatic Lung Cancer: Impact on Real World Outcomes
Wu, J., Ding, V., Luo, S., Choi, E., Hellyer, J., Myall, N., … Han, S. (2021). A Predictive Model to Guide Brain MRI Surveillance in Patients With Metastatic Lung Cancer: Impact on Real World Outcomes. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
Survival After Distant Recurrent Versus De Novo Stage IV Metastatic Lung Cancer Under Low-Dose Computed Tomography Screening
Su, C., Choi, E., Wu, J., Neal, J., Kurian, A., Backhus, L., … Han, S. (2021). Survival After Distant Recurrent Versus De Novo Stage IV Metastatic Lung Cancer Under Low-Dose Computed Tomography Screening. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.
Padda, S. K., Reckamp, K. L., Koczywas, M., Neal, J. W., Kawashima, J., Kong, S., … Wakelee, H. A. (2021). A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. -
Mobocertinib in EGFR Exon 20 InsertionePositive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy
Spira, A., Ramalingam, S., Neal, J., Piotrowska, Z., Mekhail, T., Tsao, A., … Janne, P. (2021). Mobocertinib in EGFR Exon 20 InsertionePositive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC.
Aredo, J. V., Hellyer, J. A., Neal, J. W., & Wakelee, H. A. (2021). Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 16(12), 1994–1998. -
Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents
Lau, B., No, H. J., Wu, Y. F., Ko, R. B., Devine, M., Das, M., … Vitzthum, L. (2021). Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer
Devine, M., Merriott, D. J., Say, C., Yoo, C., Yi, E., Lau, B., … Vitzthum, L. (2021). Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR)
Gensheimer, M. F., Gee, H. E., Von Eyben, R., Shirato, H., Taguchi, H., Wong, S., … Diehn, M. (2021). A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR). INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations.
Ou, S.-H. I., Lin, H. M., Hong, J.-L., Yin, Y., Jin, S., Lin, J., … Neal, J. W. (2021). Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
CONTACT-01: A phase III, randomized study of atezolizumab plus cabozantinib versus docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC) previously treated with PD-L1/PD-1 inhibitors and platinum-containing chemotherapy.
Neal, J. W., Kundu, P., Tanaka, T., Enquist, I., Patel, S., Balestrini, A., … Kim, S.-W. (2021). CONTACT-01: A phase III, randomized study of atezolizumab plus cabozantinib versus docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC) previously treated with PD-L1/PD-1 inhibitors and platinum-containing chemotherapy. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer.
Hellyer, J. A., White, M. N., Gardner, R. M., Cunanan, K., Padda, S. K., Das, M., … Wakelee, H. A. (2021). Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer. Clinical Lung Cancer. -
Radiological tumor classification across imaging modality and histology.
Wu, J., Li, C., Gensheimer, M., Padda, S., Kato, F., Shirato, H., … Li, R. (2021). Radiological tumor classification across imaging modality and histology. Nature Machine Intelligence, 3, 787–798. -
Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.
White, M. N., Piper-Vallillo, A. J., Gardner, R. M., Cunanan, K., Neal, J. W., Das, M., … Wakelee, H. A. (2021). Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. Clinical Lung Cancer. -
The Survival Impact of Second Primary Lung Cancer in Patients with Lung Cancer.
Choi, E., Luo, S. J., Aredo, J. V., Backhus, L. M., Wilkens, L. R., Su, C. C., … Han, S. S. (2021). The Survival Impact of Second Primary Lung Cancer in Patients with Lung Cancer. Journal of the National Cancer Institute. -
Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer.
Aredo, J. V., Wakelee, H. A., Neal, J. W., & Padda, S. K. (1800). Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer. Cancer Treatment and Research Communications, 30, 100497. -
Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer.
Padda, S. K., Aredo, J. V., Vali, S., Singh, N. K., Vasista, S. M., Kumar, A., … Wakelee, H. A. (2021). Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer. JCO Precision Oncology, 5, 153–162. -
EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor.
Goldman, J. W., Karlovich, C., Sequist, L. V., Melnikova, V., Franovic, A., Gadgeel, S. M., … Wakelee, H. A. (2018). EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor. JCO Precision Oncology, 2, 1–13. -
Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer
Chao, Y., Zhou, J., Hsu, S., Ding, N., Li, J., Zhang, Y., … Hu, J. (2022). Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer. TRANSLATIONAL LUNG CANCER RESEARCH. -
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA.
Remon, J., Lacas, B., Herbst, R., Reck, M., Garon, E. B., Scagliotti, G. V., … Besse, B. (2022). ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. European Journal of Cancer (Oxford, England : 1990), 166, 112–125. -
Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer.
Chao, Y., Zhou, J., Hsu, S., Ding, N., Li, J., Zhang, Y., … Hu, J. (2022). Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer. Translational Lung Cancer Research, 11(2), 295–306. -
Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.
Shah, M. P., & Neal, J. W. (2022). Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer. Drugs. -
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma.
Govindan, R., Aggarwal, C., Antonia, S. J., Davies, M., Dubinett, S. M., Ferris, A., … Herbst, R. S. (2022). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. Journal for Immunotherapy of Cancer, 10(5). -
High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.
Piper-Vallillo, A. J., Rotow, J. K., Aredo, J. V., Shaverdashvili, K., Luo, J., Carlisle, J. W., … Piotrowska, Z. (2022). High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience. JTO Clinical and Research Reports, 3(6), 100328. -
Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms.
No, H. J., Raja, N., Von Eyben, R., Das, M., Roy, M., Myall, N., … Vitzthum, L. K. (2022). Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms. International Journal of Radiation Oncology, Biology, Physics. -
Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.
Zhu, H., Galdos, F. X., Lee, D., Waliany, S., Vivian Huang, Y., Ryan, J., … Wu, S. M. (2022). Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis. Circulation, 101161CIRCULATIONAHA121056730. -
Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens.
Waliany, S., Wakelee, H., Ramchandran, K., Das, M., Huang, J., Myall, N., … Neal, J. W. (2022). Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens. Clinical Lung Cancer. -
Systematic pan-cancer analysis of mutation-treatment interactions using large real-world clinicogenomics data.
Liu, R., Rizzo, S., Waliany, S., Garmhausen, M. R., Pal, N., Huang, Z., … Zou, J. (2022). Systematic pan-cancer analysis of mutation-treatment interactions using large real-world clinicogenomics data. Nature Medicine. -
Clinicopathological characteristics and prognostic significance of HDAC11 protein expression in non-small cell lung cancer: a retrospective study.
Lu, D., Ma, Z., Huang, D., Zhang, J., Li, J., Zhi, P., … Wang, J. (2022). Clinicopathological characteristics and prognostic significance of HDAC11 protein expression in non-small cell lung cancer: a retrospective study. Translational Lung Cancer Research, 11(6), 1119–1131. -
Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer.
Devine, M., Merriott, D. J., No, H. J., Lau, B., Say, C., Yoo, C., … Vitzthum, L. K. (2022). Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer. Practical Radiation Oncology. -
Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study.
Chu, T., Zhang, W., Zhang, B., Zhong, R., Zhang, X., Gu, A., … Han, B. (2022). Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study. Translational Lung Cancer Research, 11(7), 1394–1404. -
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review.
Graham, J., Vogel, A., Cheng, A.-L. L., Bjarnason, G. A., & Neal, J. W. (2022). Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review. Cancer Treatment Reviews, 110, 102453. -
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A (vol 40, pg 2295, 2022)
Reckamp, K. L., Redman, M. W., Dragnev, K. H., Minichiello, K., Villaruz, L. C., Faller, B., … Herbst, R. S. (2022). Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A (vol 40, pg 2295, 2022). JOURNAL OF CLINICAL ONCOLOGY, 40(25), 3002. -
Predictive Model to Guide Brain Magnetic Resonance Imaging Surveillance in Patients With Metastatic Lung Cancer: Impact on Real-World Outcomes.
Wu, J., Ding, V., Luo, S., Choi, E., Hellyer, J., Myall, N., … Han, S. S. (2022). Predictive Model to Guide Brain Magnetic Resonance Imaging Surveillance in Patients With Metastatic Lung Cancer: Impact on Real-World Outcomes. JCO Precision Oncology, 6, e2200220. -
Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer.
Hui, C., Qu, V., Wang, J.-Y. Y., von Eyben, R., Chang, Y.-C. C., Chiang, P.-L. L., … Pollom, E. (2022). Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer. Journal of Neuro-Oncology. -
Phenotyping Malignant Pleural Effusions with Mass Cytometry: Evidence of EMT and MET States in Late-Stage NSCLC
Karacosta, L. G., Pancirer, D., Preiss, J., Shrager, J. B., Sung, A. W., Neal, J. W., … Plevritis, S. K. (2022). Phenotyping Malignant Pleural Effusions with Mass Cytometry: Evidence of EMT and MET States in Late-Stage NSCLC. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
Cabozantinib Plus Atezolizumab in First or Second-Line Advanced NSCLC and Previously-Treated EGFR Mutant Advanced NSCLC
Neal, J. W., Lim, F. L., Aix, S. P., Viteri, S., Santoro, A., Spencer, K., … Felip, E. (2022). Cabozantinib Plus Atezolizumab in First or Second-Line Advanced NSCLC and Previously-Treated EGFR Mutant Advanced NSCLC. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
Matching-adjusted indirect comparison (MAIC) of mobocertinib versus amivantamab in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins).
Ou, S.-H. I., Prawitz, T., Lin, H. M., Hong, J.-L., Tan, M., Proskorovsky, I., … Neal, J. W. (2022). Matching-adjusted indirect comparison (MAIC) of mobocertinib versus amivantamab in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Representativeness of patients enrolled in the Lung Cancer Master Protocol (Lung-MAP).
Vaidya, R., Unger, J. M., Qian, L., Minichiello, K., Herbst, R. S., Gandara, D. R., … Redman, M. W. (2022). Representativeness of patients enrolled in the Lung Cancer Master Protocol (Lung-MAP). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non-small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.
Neal, J. W., Santoro, A., Viteri, S., Aix, S. P., Fang, B., Lim, F. L., … Felip, E. (2022). Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non-small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Phase 2 EVOKE-02 Study of Sacituzumab Govitecan and Pembrolizumab +/- Platinum in First-Line Metastatic NSCLC
Reck, M., Liu, S. V., Owen, S. P., Garon, E. B., Neal, J. W., Vicente, D., … Mok, T. S. K. (2022). Phase 2 EVOKE-02 Study of Sacituzumab Govitecan and Pembrolizumab +/- Platinum in First-Line Metastatic NSCLC. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non-small cell lung cancer (NSCLC).
Garon, E. B., Liu, S. V., Owen, S. P., Reck, M., Neal, J. W., Vicente, D., … Mok, T. S. K. (2022). EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Efficacy of osimertinib in patients with EGFR mutant lung cancer harboring the uncommon exon 19 deletion, L747_A750>P.
Grant, M. J., Aredo, J. V., Starrett, J., Wurtz, A., Piotrowska, Z., Piper-Vallillo, A., … Goldberg, S. B. (2022). Efficacy of osimertinib in patients with EGFR mutant lung cancer harboring the uncommon exon 19 deletion, L747_A750>P. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Neighborhood socioeconomic disadvantage, tobacco use, and cessation indicators among adults with cancer in the United States: Results from 10 ECOG-ACRIN trials.
Walter, A. W., Lee, J.-W., Gareen, I. F., Kircher, S. M., Herman, B. A., Streck, J. M., … Park, E. R. (2022). Neighborhood socioeconomic disadvantage, tobacco use, and cessation indicators among adults with cancer in the United States: Results from 10 ECOG-ACRIN trials. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.
Gensheimer, M. F., Gupta, D., Patel, M. I., Fardeen, T., Hildebrand, R., Teuteberg, W., … Ramchandran, K. (2022). Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer. JCO Oncology Practice, OP2200128. -
Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer.
Aredo, J. V., Wakelee, H. A., Hui, A. B.-Y., Padda, S. K., Joshi, N. D., Guo, H. H., … Neal, J. W. (2022). Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer. Cancer Treatment and Research Communications, 33, 100659. -
Feasibility of large scale distress screening at an academic center and associated network sites using an adapted patient-reported outcome instrument and reflexive suicide screening.
Gupta, D. M., Savadamuthu, V., Qin, F. F., Roy, M., Herring, J. B., Robinson, A., … Ramchandran, K. (2022). Feasibility of large scale distress screening at an academic center and associated network sites using an adapted patient-reported outcome instrument and reflexive suicide screening. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity
Huang, Y. V., Waliany, S., Lee, D., Galdos, F. X., Witteles, R. M., Neal, J. W., … Zhu, H. (2022). The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity. JACC: CardioOncology, 4(5). -
The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity.
Huang, Y. V., Waliany, S., Lee, D., Galdos, F. X., Witteles, R. M., Neal, J. W., … Zhu, H. (2022). The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity. JACC. CardioOncology, 4(5), 629–634. -
Diagnosis and treatment of pericardial mesothelioma by mediastinal mass resection: a case report
Liang, L., Zhang, X., Ke, X., Song, Y., Brcic, L., Neal, J. W., … Chen, C. (2022). Diagnosis and treatment of pericardial mesothelioma by mediastinal mass resection: a case report. ANNALS OF TRANSLATIONAL MEDICINE. -
Diagnosis and treatment of pericardial mesothelioma by mediastinal mass resection: a case report.
Liang, L., Zhang, X., Ke, X., Song, Y., Brcic, L., Neal, J. W., … Chen, C. (2022). Diagnosis and treatment of pericardial mesothelioma by mediastinal mass resection: a case report. Annals of Translational Medicine, 10(24), 1407. -
Amivantamab in combination with lazertinib in patients with atypical epidermal growth factor receptor (EGFR) mutations excluding exon 20 insertion mutations: Initial results from CHRYSALIS-2
Cho, B. C., Wang, Y., Li, Y., Wu, L., Besse, B., Marmarelis, M. E., … Tomasini, P. (2022). Amivantamab in combination with lazertinib in patients with atypical epidermal growth factor receptor (EGFR) mutations excluding exon 20 insertion mutations: Initial results from CHRYSALIS-2. ANNALS OF ONCOLOGY. ELSEVIER. -
Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study.
Ji, J., Aredo, J. V., Piper-Vallillo, A., Huppert, L., Rotow, J. K., Husain, H., … Riess, J. W. (2023). Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study. JTO Clinical and Research Reports, 4(3), 100459. -
Pharmacovigilance Analysis of HeartFailure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer.
Waliany, S., Caswell-Jin, J., Riaz, F., Myall, N., Zhu, H., Witteles, R. M., & Neal, J. W. (2023). Pharmacovigilance Analysis of HeartFailure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer. JACC. CardioOncology, 5(1), 85–98. -
Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations.
Grant, M. J., Aredo, J. V., Starrett, J. H., Stockhammer, P., van Alderwerelt van Rosenburgh, I. K., Wurtz, A., … Goldberg, S. B. (2023). Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Long term effect of radiotherapy on risk of second primary lung cancer and overall mortality among lung cancer patients
Choi, E., Lam, V. T., Aredo, J. A., Kumar, A. V., Wampfler, J., Wu, J. T., … Han, S. S. (2022). Long term effect of radiotherapy on risk of second primary lung cancer and overall mortality among lung cancer patients. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors.
Sun, T. Y., Nguyen, B., Chen, S. B., Natkunam, Y., Padda, S., van de Rijn, M., … Riess, J. W. (2023). Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors. JTO Clinical and Research Reports, 4(4), 100498. -
Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging.
Alhusaini, S., Lanman, T. A., Ko, R. B., Therkelsen, K. E., Eyben, R. V., Diehn, M., … Nagpal, S. (2023). Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging. Frontiers in Oncology, 13, 1139940. -
Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.
Ou, S.-H. I., Lin, H. M., Hong, J.-L. L., Yin, Y., Jin, S., Lin, J., … Neal, J. W. (2023). Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison. Lung Cancer (Amsterdam, Netherlands), 179, 107186. -
Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents.
Lau, B., Wu, Y. F., No, H. J., Ko, R. B., Devine, M., Das, M. S., … Vitzthum, L. K. (2023). Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. -
PROVIDER INSIGHTS ON MANAGING PATIENTS ON IMMUNOTHERAPY, BARRIERS TO CLINICAL TRIALS, AND BIOMARKER TESTING PREFERENCES
Ackbarali, T., Neal, J., Janjigian, Y., & Overman, M. (2022). PROVIDER INSIGHTS ON MANAGING PATIENTS ON IMMUNOTHERAPY, BARRIERS TO CLINICAL TRIALS, AND BIOMARKER TESTING PREFERENCES. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP. -
Dissecting metastasis using preclinical models and methods.
Hebert, J. D., Neal, J. W., & Winslow, M. M. (2023). Dissecting metastasis using preclinical models and methods. Nature Reviews. Cancer. -
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study.
Saad, M. B., Hong, L., Aminu, M., Vokes, N. I., Chen, P., Salehjahromi, M., … Wu, J. (2023). Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. The Lancet. Digital Health. -
Second Primary Lung Cancer among Lung Cancer Survivors Who Never Smoked
Choi, E., Su, C., Wu, J., Aredo, J., Neal, J., Leung, A., … Han, S. (2023). Second Primary Lung Cancer among Lung Cancer Survivors Who Never Smoked. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) plus cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy
Neal, J., Pavlakis, N., Kim, S.-W., Goto, Y., Lim, S. M., Mountzios, G., … Newsom-Davis, T. (2023). CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) plus cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal.
Bestvina, C. M., Garassino, M. C., Neal, J. W., Wakelee, H. A., Diehn, M., & Vokes, E. E. (2023). Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2300258. -
Cigarette and alternative tobacco product use among adult cancer survivors enrolled in 9 ECOG-ACRIN clinical trials.
Streck, J. M., Lee, J.-W., Walter, A. W., Rosen, R. L., Gareen, I. F., Kircher, S. M., … Ostroff, J. S. (2023). Cigarette and alternative tobacco product use among adult cancer survivors enrolled in 9 ECOG-ACRIN clinical trials. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. -
Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked.
Bodor, J. N., Patel, J. D., Wakelee, H. A., Levy, B. P., Borghaei, H., Pellini, B., … Treat, J. (2023). Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked. Clinical Lung Cancer. -
Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
Patel, S. R., & Neal, J. W. (2023). Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer? TRANSLATIONAL LUNG CANCER RESEARCH. -
Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
Patel, S. R., & Neal, J. W. (2023). Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer? Translational Lung Cancer Research, 12(7), 1631–1635. -
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP).
Vaidya, R., Unger, J. M., Qian, L., Minichiello, K., Herbst, R. S., Gandara, D. R., … Redman, M. W. (2023). Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP). JCO Precision Oncology, 7, e2300218. -
Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial.
Gensheimer, M. F., Gee, H., Shirato, H., Taguchi, H., Snyder, J. M., Chin, A. L., … Diehn, M. (2023). Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial. JAMA Oncology. -
Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations.
Ou, S.-H. I., Lin, H. M., Hong, J.-L. L., Yin, Y., Jin, S., Lin, J., … Neal, J. W. (2023). Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations. JTO Clinical and Research Reports, 4(10), 100558. -
Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.
Wolf, J., Souquet, P.-J. J., Goto, K., Cortot, A., Baik, C., Heist, R., … Awad, M. M. (2023). Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review. Clinical Lung Cancer. -
Overall Survival Among Patients With De Novo Stage IV Metastatic and Distant Metastatic Recurrent Non-Small Cell Lung Cancer.
Su, C. C., Wu, J. T., Choi, E., Myall, N. J., Neal, J. W., Kurian, A. W., … Han, S. S. (2023). Overall Survival Among Patients With De Novo Stage IV Metastatic and Distant Metastatic Recurrent Non-Small Cell Lung Cancer. JAMA Network Open, 6(9), e2335813. -
EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC)
Nassar, A., Adib, E., Feng, J., Aredo, J. V., Parikh, K., Harris, J. P., … Kim, S. Y. (2023). EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP
Mack, P. C., Redman, M. W., Kozono, D. E., Callis, S., Tukachinsky, H., Tolba, K. A., … Gandara, D. R. (2023). The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Risk factors for venous thromboembolism (VTE) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone.
Girard, N., Cho, B. C., Spira, A. I., Shu, C. A., Sanborn, R. E., Neal, J. W., … Hayashi, H. (2023). Risk factors for venous thromboembolism (VTE) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Mobocertinib efficacy in patients with NSCLC and EGFR exon 20 insertion mutations (ex20ins) identified by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA)
Neal, J. W., Li, Y., Yu, Z., Fram, R. J., Danes, C., Vincent, S., & Piotrowska, Z. (2023). Mobocertinib efficacy in patients with NSCLC and EGFR exon 20 insertion mutations (ex20ins) identified by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).
Padda, S. K., Redman, M. W., Gerber, D. E., Stinchcombe, T., Waqar, S. N., Leal, T., … Neal, J. W. (2023). ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC.
Hui, C., Wakelee, H. A., Neal, J. W., Ramchandran, K. J., Das, M., Nagpal, S., … Myall, N. (2023). CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC. International Journal of Radiation Oncology, Biology, Physics, 117(2S), e110. -
The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine ECOG-ACRIN Cancer Research Group (EA) trials.
Walter, A. W., Lee, J.-W. W., Streck, J. M., Gareen, I. F., Herman, B. A., Kircher, S. M., … Park, E. R. (2023). The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine ECOG-ACRIN Cancer Research Group (EA) trials. Cancer. -
Risk model-based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model.
Choi, E., Luo, S. J., Ding, V. Y., Wu, J. T., Kumar, A. V., Wampfler, J., … Han, S. S. (2023). Risk model-based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model. Cancer. -
Osimertinib-Associated Cardiomyopathy In Patients With Non-Small Cell Lung Cancer: A Case Series
Franquiz, M., Waliany, S., Xu, A., Hnatiuk, A., Wu, S., Cheng, P., … Zhu, H. (2023). Osimertinib-Associated Cardiomyopathy In Patients With Non-Small Cell Lung Cancer: A Case Series. JACC: CardioOncology, 839–841. -
Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US.
Choi, E., Ding, V. Y., Luo, S. J., Ten Haaf, K., Wu, J. T., Aredo, J. V., … Han, S. S. (2023). Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US. JAMA Oncology. -
Second Primary Lung Cancer Among Lung Cancer Survivors Who Never Smoked.
Choi, E., Su, C. C., Wu, J. T., Aredo, J. V., Neal, J. W., Leung, A. N., … Han, S. S. (2023). Second Primary Lung Cancer Among Lung Cancer Survivors Who Never Smoked. JAMA Network Open, 6(11), e2343278. -
Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial.
Hui, C., Brown, E., Wong, S., Das, M., Wakelee, H., Neal, J., … Vitzthum, L. K. (2023). Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial. Clinical Lung Cancer. -
Phenotyping EMT and MET cellular states in lung cancer patient liquid biopsies at a personalized level using mass cytometry.
Karacosta, L. G., Pancirer, D., Preiss, J. S., Benson, J. A., Trope, W., Shrager, J. B., … Plevritis, S. K. (2023). Phenotyping EMT and MET cellular states in lung cancer patient liquid biopsies at a personalized level using mass cytometry. Scientific Reports, 13(1), 21781. -
Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small-Cell Lung Cancer.
Hui, C., Marquez, C., Lau, B., Das, M., Myall, N. J., Roy, M., … Vitzthum, L. K. (2023). Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small-Cell Lung Cancer. Clinical Lung Cancer. -
Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research
Chan, A., Torelli, S., Cheng, E., Batchelder, R., Waliany, S., Neal, J., … Zhu, H. (2023). Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research. Current Treatment Options in Cardiovascular Medicine. -
Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.
Ou, S.-H. I., Prawitz, T., Lin, H. M., Hong, J.-L. L., Tan, M., Proskorovsky, I., … Neal, J. W. (2023). Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison. Clinical Lung Cancer. -
Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research.
Chan, A., Torelli, S., Cheng, E., Batchelder, R., Waliany, S., Neal, J., … Zhu, H. (2023). Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research. Current Treatment Options in Cardiovascular Medicine, 25(12), 715–735. -
Molecular Distribution of Patients with Non-Small Cell Lung Cancer Eligible for Lung Cancer Screening
Aredo, J. V., Neal, J. W., Kunder, C. A., Ramchandran, K. J., Das, M. S., Myall, N. J., … Wakelee, H. A. (2023). Molecular Distribution of Patients with Non-Small Cell Lung Cancer Eligible for Lung Cancer Screening. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
Demographic and Genomic Characteristics of Non-Small Cell Lung Cancer Patients with ARID1A Alterations
Al-Obeidi, E., Williams, A., Burkert, N., Pepin, K., Hicks, J. K., Gray, J. E., … Gandara, D. (2023). Demographic and Genomic Characteristics of Non-Small Cell Lung Cancer Patients with ARID1A Alterations. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study.
Nassar, A. H., Kim, S. Y., Aredo, J. V., Feng, J., Shepherd, F., Xu, C., … Goldberg, S. B. (2024). Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. -
HER2-Mutant Advanced and/or Metastatic Non-Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes.
Waliany, S., Neal, J. W., Engel-Nitz, N., Lam, C., Lin, F., Park, L., … Nagasaka, M. (2024). HER2-Mutant Advanced and/or Metastatic Non-Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes. Clinical Lung Cancer. -
Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 165,912US patients.
Liu, R., Wang, L., Rizzo, S., Garmhausen, M. R., Pal, N., Waliany, S., … Zou, J. (2024). Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 165,912US patients. Cell Reports. Medicine, 101444. -
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.
Neal, J., Pavlakis, N., Kim, S.-W. W., Goto, Y., Lim, S. M., Mountzios, G., … Newsom-Davis, T. (2024). CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2302166. -
A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol.
Neal, J. W., Minichiello, K., Brennick, R., Huang, R. S., Hiemenz, M. C., Amler, C., … Kozono, D. E. (2024). A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol. The Oncologist. -
Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.
Shah, A. T., Blanchard, I., Padda, S. K., Wakelee, H. A., & Neal, J. W. (2024). Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Clinical Lung Cancer. -
Efficacy and safety of sintilimab in combination with chemotherapy for recurrent extensive-stage small cell lung cancer: a real-world retrospective study.
Wang, J., Liang, S., Xu, L., Kong, Y., Seki, N., Ganti, A. K., … Chen, B. (2024). Efficacy and safety of sintilimab in combination with chemotherapy for recurrent extensive-stage small cell lung cancer: a real-world retrospective study. Journal of Thoracic Disease, 16(6), 3897–3908.
-
Induction of FucT-VII by the Ras/MAP kinase cascade in Jurkat T cells
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors
- Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
- A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
- Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
- Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
- Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)
- Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy
- Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
- Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
- SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer
Practice Locations
Thoracic Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Thoracic Cancer Program in Palo Alto
875 Blake Wilbur Dr
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereCancer Immunotherapy Program Palo Alto, CA
Palo Alto, CA
Cancer Immunotherapy Program
875 Blake Wilbur Dr
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(226 reviews)
We greatly appreciate all the kind care we received from Dr Neal and his team.
I felt reassured by the visit and hopeful by Dr. Joe Neil said
Nice, knowledgeable, kind, funny
Dr. Joel Neal is a great doctor. He is really good at answering all questions and explaining treatment.
Outstanding physician, a beacon in the sea of medicine and science! My wife and I feel so fortunate to be cared for by such a caring and knowledgeable doctor, thank you!
Thank you Dr. Neal,
Dr. Neal saved my life. Full stop. Without his treatment strategy and his orchestration of Stanford health diagnostic and therapeutic resources, and Asta Zeneca's drug Tagrisso, I would be long gone. He and his team have been realistic but encouraging throughout this difficult journey. He has a charming sense of humor that puts my wife and me at ease.
I would not want to leave out Dr. Billy Loo and his team. The SABR treatment that he applied and the he and Dr. Neal recommended put a definitive end to the remains of my tumor, which completed the main treatment cycle.
All my questions were answered. This was an effective visit.
Dr Neal is the best really appreciate him
Very through doctor.
He seems knowledgable and personable.
Excellent doctor! He explains everything
Excellent
Extremely knowledgeable and helpful. Also kind.
Great doctor!
Appreciate his expertise
excellent doctor, great listener, able to create a treatment plan that offers hope and addresses all concerns!
Dr. Neal is so obviously competent in his job, and has great backup. Like from Matthew today.
But his upbeat, engaging personality also makes him outstanding in my experience.
I consider myself to be very fortunate to receive medical care from Dr. Neal and his great team. I wish that everyone could receive this type of care. I pray for him and his team.
Dr Neal is very knowledgeable of the newest medications and techniques. He is patient and kind and very truthful.
Dr Neal is an excellent oncologist. He is approachable, caring and provides the right level of information to me. I would recommend him to anyone who needs a thoracic oncologist.
Excellent positive attitude and clinician
Dr. Neal is extremely professional. To me, he is the best doctor. I would like to recommend him to other people who need a doctor in Stanford Health Care.
Very knowledgeable and straightforward person
Dr Neal is particularly wonderful in his ability to explain all the detailed aspects of my cancer and the treatment he has ordered. His compassionate and deep attention to my mental and emotional health is greatly apprecisted. His suggestions for enhancing and attaining the best quality of life are reminders of universal truths and his supportive, nonjudgmental delivery of all related advice is the hallmark of his style and professionalism.
His assistant Judy Patigma (sp?)is attentive to my questions and very clear in her answers. She briefs Dr Neal thoroughly and I appreciate the time she takes to listen. I’m appreciative of assistant Clare’s transcriptions of my appointment.
I am extremely grateful and proud to be under Dr Neal’s care.
Mitzi Konevich
He is a premier doctor and human. I believe in his expertise explicitly
Great doctor! Thorough, understanding, knowledgeable, quick.
Just to thank Dr. Neal for his suggestions and help.
Dr Neal is an excellent doctor. After a surprising and difficult diagnosis over 5 years ago, he has kept me moving forward with good health, optimism, and great confidence in him. Thank you!
Dr. Neal is so good at listening. I appreciate that very much.
Dr. Joel Neal is a very caring and professional doctor
He is taking care of me for the past 4 years and I am extremely happy with his care for my disease.
I will recommend him to all .
Thank you Dr. Neal
Dr. Neal is a extremely competent physician with an excellent manner and I would recommend him to anyone and everyone.
Even though I had not seen Dr Neal since 2016, the conversation was like I had just been in. He had my history at his disposal and is very personable.
Dr. Neal saved my life. By which I mean, he orchestrated the amazing resources of Stanford Health to diagnose, plan and treat my Stage 4 non small-cell lung cancer definitively. I was lucky that the biopsy revealed that I had EGFR Exon 19 deletion, but Dr. Neal made it happen for me to get Tagrisso immediately for first line treatment. I felt that I was in the care of someone who would marshall the best available treatments to get me through that dark time. Later, when the tumor had retreated 75% and I had been stable for several years, he collaborated with Dr. Loo, who attacked the remaining tumor with SABR. Now, with "no evidence of disease," but knowing that NSCLC or some other cancer could appear in the future, I am confident that I am in the best possible hands with Dr. Neal and his colleagues at Stanford Health.
Good Provider with Love & Care
Dr. Neal has been my favorite doctor for sometime now!
Dr Neal once again exceeded all of my expectations by clearly answering my many questions and especially by providing advice relevant to my care and referring me to various specific spécialiséd resources to help me get involved proactively in the management of my care treatment and all aspects of my wellbeing. I am very grateful to Dr Neal for his attention and compassion. Dr Neal’s team is excellent. The team was very helpful to inquire about my questions to expediently prepare Dr Neal to meet with me.
Is able to consolidate medical information so it can be understood and assist with a treatment plan
Wonderful caring doctor. Excellent skills
Dr. Neal is awesome!
Excellent visit with Dr Neal. He brief me on my upcoming treatment and the choices I have to make . Everything was clear and uderstanderable.
Excellent Doctor
Dr Neal is kind, considerate, knowledgeable, precise and informative, logical and compassionate. I trust his opinion and treatment plans implicitly. I can rely on him completely to suggest and provide the best possible care for my health issues. His professionalism and kind personality are extraordinary.
Dr. Neal is the best doctor I ever met.
Excellent presentation - Dr. Neal made me feel better about my circumstances overall.
Dr. Neal and his team is the BEST! He is not only an excellent clinician, but a lovely person who really cares about his patients.
wonderful doctor
Stanford is the best when it comes to health care.
Very good!
So knowledgeable. Willing to explain and even continue looking at my case.
Dr Neal listens and answers all my questions .
The best
concerned, courteous, informative , feel fortunate to have him on my team!
Dr. Joel Neal is a fantastic doctor! I feel so very lucky to have him managing my cancer treatment. He is completely honest, empathetic, and kind, as well as being humorous, and he is excellent at explaining CT scans and treatment options. Having Dr. Neal gives me great peace of mind! I could not be more thankful and grateful to have him as my doctor!
Excellent pre-session with a fellow on his last day and had good meeting with doctor Neal. Always very positive approach to treatment which must be hard seeing so many people with an incurable cancer.
Dr. Neal was very friendly, courteous and informative. I got answers to my questions and have decided on a path forward. I did not feel rushed or that any of my concerns were dismissed.
Dr. Neal n his staffs are thorough throughout the process. A staff member reviewed and updated my clinical progress/changes, received our questions/concerns, and presented/discussed with Dr. Neal before he came on live. Dr Neal delivered great cares in addressing our concerns, answering our questions, and recommending his plan of care for the future.
As always, he was entirely understanding and helpful.
Dr Neal answered my questions and was very pleasant. Would definitely recommend his practice to friends and family.
Dr. Neal was great. Thank you for your time.
An excellent doctor who cares deeply about his patients. I am so grateful he's on my care team.
Dr Neal is very kind and knowledgeable. I especially value His wisdom and empathy as I navigate life post treatment. He is an extraordinary medical professional and I appreciate his strong positive character and integrity as a fellow human in the journey of life
I have no comment. I appreciated having the conversation and learned a few things that will be helpful.
Fine physican, excellent rapport, knowledgeable, great personality, encouraging, great!
Dr. Neal is a very knowledgeable and compassionate oncologist. I am extremely grateful to him!
Dr Neal and his team are great and I rave to anyone who will listen.
He is very professional and easy to talk with.
I visited him for a second opinion and he helped to lay out the options very clearly and explained the pros and cons better than anyone has so far. It was very helpful.
The call went well and all my questions were answered.
Compassionate, knowledgeable, personable, able to provide excellent medical care for complex medical issues! No matter what the outcome we always feel stronger after our appointments!
A true gentleman and a humble physician.
A very professional and personal physician. He is very interested in the benefits of his patients.
Dr Neal is amazing! Experienced, knowledgeable, kind, and extremely helpful. I feel that he has my best interests at heart.
Always a pleasant encounter
Dr. Neal was very kind, considerate, warm and engaging. I like his expertise and also his positive attitude. He said he would do the worrying for me, and I really appreciated that comment. It is such a scary thing to have cancer, and having someone this good on my team makes me feel hopeful. Thank you.
Dr. Neal is the BEST! Caring, very thorough in explaining conditions and treatments. Was not at all made to feel rushed. Overall, I’d give Dr Neal a 5 star recommendation.
Very professional and friendly
My visit with Dr. Joel Neal was affirming and very informative. He was very kind and I am grateful for the advice and support. I feel uplifted and energized to deal with my future and my health status. He's the BEST!
He saved my life, for which I am of courseI eternally grateful. He has been an immense pleasure to work with as well as full of reality-based insight, counsel and recommendations. We have worked together for nearly 4 years and I am now on a really good path.
Dr Neal made me feel I had his full attention in n, was generous with information on possible treatments. He was
excellent support
The whole team has been most helpful, courteous and caring.
Thank you Dr. Neal!
Compassion
had a great visit
I am satisfied with the time he gave me as well as his expert opinion on my situation
Personable, informative, caring engaging!
Being with Dr. Neal for 5 years I have the most respect and love for his tender care of me andI know everyone else he treats.
I had a very good experience with this second opinion visit with Dr. Neal
We are grateful for Dr Neal's guidance regarding treatment/immunotherapy going forward and his discussion of PET scan results. We believe God has blessed us with Dr Neal.
Dr, Neal is the epitome of kindness and care. He is more than a doctor, he is a healer.
He was very informative and helpful.
Really clear, empathic, informed, and hoping he can help me on this (unwanted) journey. Also very human.
Caring, professional and kind!
Dr. Neal is just wonderful! He is extremely knowledgeable and specific and truly seems to care. I deeply appreciate his expertise in my lung cancer.
The doctor is very nice! He untied some of my heart and made me more confident. I sincerely thank him.
Dr. Neal is very caring and does understand the patient’s condition and point of view.
I am very impressed with the whole entire team.
Best care ever - The medical team and I have a great relationship. I feel very fortunate
Joel seems like a very nice person. He was personable. He talked to me so I understood what he was talking about. I would recommend him.
Knowledgeable, professional, interacts well with patient and assistant. Would strongly recommend him to those whom are in need of his abilities!
Dr. Neal and his team were exceptional at building rapport via video and addressing my concerns, Although I had several questions, the team and Dr. Neal took the time to answer all my questions and explain treatment options. At no point did I feel rushed or that my questions were trivial. Dr. Neal was also great at addressing the emotional aspect of living with cancer.
He was great.
Dr. Neal is the best. I don’t wish cancer on anyone but if you are unfortunately diagnosed with lung cancer Dr. Neal is the person to see.
Great staff
He explained purpose of visit clearly, and made me feel very much at ease.
Excellent ! Very caring and extremely professional and he is a treasure!
Dr.Neal is the best, he took time asking questions & explained clearly all my concerns. He provided the future plans of treatment really carefully for my health. Thank you so much Dr. Neal 🙠🠼 😀
Excellent rapport with the patient, shows genuine concern and empathy. Knowledgeable and able to impart this to the patient, in this case myself. Thorough in regards to present findings as well as actions to be taken in the future.
In short he rocks!!!!!!!
I appreciated the thoroughness and detail of the consultation. His recommendations were a good option that had not be considered before.
He’s terrific!!
Just great! And the NP (Judy) working with Dr. Neal was excellent as well.
Dr. Neal communicates very effectively.
Very helpful, listened and gave clear opinions. Easy to understand.
Dr. Neal took the time to review my file and prior surgeries/scans/reports, before continuing the video session. Three things stood out:
1) He took the time to study my case and formulated a clear and concise opinion.
2) Based on the given facts, he explained his assessments, as well as recommend another 2nd opinion with Stanford radiology, before proceeding with cyberknife procedure.
3) Because Dr. Neal had plenty of time to study my case, I felt reassured that his assessment was formulated after careful consideration and joint consultation with Dr. Thomas Sun.
Very comfortable to converse with. Very thorough. Very clear.
excellent Doctor
Excellent doctor providing second opinion on lung tumor advise to my Honolulu doctor. Working as a team. His opinion is priceless.
We continue to appreciate your professional comments to help treat my cancer.
Excellent give excellent guidance and advice
He did a great job and explained the problems and possible solutions.
He is very nice , friendly and knowledgeable. He helped coordinate with the Tumor Board to provide good treatment advices.
Great doctor
Very knowledgeable and very kind.
Very engaging and attentive. Gave very good explanations to all of my questions.
Both Dr. Neal and Dr. Wu were professional, knowledgeable, caring and helpful. Very pleased with the visit.
accommodating care provider and listen to your needs
Doctor Joel Neal provided answers to questions and hope for continual treatment outside of whole brain treatment. His character provided a caring person who has knowledge and experience with the type of cancer.
We appreciated his time!
Sincerely
The Lindsey's
I am extremely grateful to have a doctor like Joel Neal in charge of my care. I fully trust Dr. Neal's judgement and appreciate the time he takes to discuss and answer my questions.
Very warm and personable individual. Explains everything quite easily. I would recommend him to any lung ca patient looking for care at Stanford.
I am extremely fortunate to have Dr. Neal as my oncologist. His clinical judgment has been unerring and his professional and caring demeanor are an ideal combination. He is as responsive to my wife's questions as to mine, which is wonderful as she and I are a team in this.
Friendly engaged professional; I’m glad he’s my doc!
Dr. Neal explained and answered all of my question about my illness. He was very thorough and positive.
He is my hero and my friend. I’m so fortunate to have found him.
Dr. Joel Neal he is a good Doctor and he is a good complete explanation whatever I’ll asking about my health or my results...
He is a good smile to me even he knows its so pain inside my mind, but he gave you a positive thoughts:)
Thanks
He was extremely knowledgeable, caring, nice and respectful. He explained everything with great details, answered all our questions patiently and in a way that was easy to understand even the complicated medical situations. We really appreciate his caring and heartfelt approach.
Smart and compassionate doctor who was well prepared for my second opinion appointment. I appreciated his input about whether I would benefit a particular treatment. He was articulate, u hurried and gave great explanations. I felt he was very personable especially when he stated that if I could he would like to hear from me once a year about how I’m doing...a little check in via email. This was amazing.
Very confident in Dr. Neal
Extremely happy with call. He explained everything perfectly and answered questions I had. Very professional as well as personal
Dr. Neal is a provider that will think of patients health and condition not only physical but boost our emtions by making me smile. I truly admired Dr. Neal for his cocerned.
Excellent service!
Dr. Neal was highly recommended, and I was very happy with him!
I feel secure in his opinion it seems more realistic than his residents.
Excellent Thoracic Oncologist.
Dr Neal is great. He explains things well, answers all questions, and shows caring and compassion.
Thanks so much for a really informative call. I am very impressed with you as being a very well trained physician with a terrific “bedside†manner. I’ll look forward to a f/u call after my next set of scans.
He has been Awesome - the best!
Dr Neal is a caring, respectful person, take time to make sure I understand all procedures. He's flexible to the my need. Thanks a lot Dr. Neal!⚘ðŸ˜
Met & exceeded ALL expectations.
Dr. Joel Neal is the best!
Dr. Joel Neal is the best!
Dr. Neal is the best!
It has been a blessing to have Dr. Neal & his team guiding us through a very difficult time. Every visit, every call & every e-mail gave us confidence that we were in the BEST hands possible. I will forever be grateful to Dr. Neal, & to all of the Stanford Cancer Center - an amazing & inspiring place of HOPE. Thank you to ALL.
Dr. Katin was very thorough and caring. He did a great work up then heard Dr. Neal went over everything in detail. They explained everything in great detail.
Judy and Dr. Neal are excellent in the care administered. They are very attentive and concerned of my well being.
Dr. Neal was very thorough, thoughtful my appointment, I understood my situation clearly.
Dr. Joel Neal is a special person. He has been blessed with special talents. No matter how my situation turns out, I know I have received the best, up to date, care possible. God bless all of you!
Dr. Neal works hard for his patients & is always good natured about answering any questions. He's tops in my book.
Dr. Neal is the best!
Always courteous & engaging.
Dr. Neal and his team are all excellent! It's wonderful knowing you're getting the best medical care & from someone who really cares.
Dr. Neal is wonderful.
Dr. Neal & NP Connie spent so much time with us & showed such care & compassion. Dr. Neal drew a diagram of treatment plan options so we could understand. We were so impressed.
Dr. Neal & PA Rodriguez are excellent. They listen, give clinical perspective and clear instructions/advice, and are compassionate and encouraging.
Dr. Neal, Joel is an exceptional physician and an amazing human being who took the time to be present during every encounter w/my husband & us!!
amazing professionals - worth the wait & other bureaucratic issues...
Dr. Neal is a wonderful doctor in all respects - he is knowledgeable & very caring.
We have seen a full team of care providers now & they are nothing but amazing. Despite the complexity of my condition, I have comfort I am getting the best care possible.
Dr. Joel Neal exceeds our expectations. He's very knowledgeable, very caring, understanding. He's always make you comfortable. Thank you Dr. Neal and also to your team of doctors & NP you bring in. Excellent!
We were not rushed. Everything explained. Gave time for us to understand and react some of the decisions. Gave us visual present situation. Very caring.
Excellent experience!!
Courteous, showed compassion & took time to answer all our concerns.
Extreme clarity, lots of openness during visit, really wonderful physician.
I love Dr. Neal.
Dr. Neal is intelligent compassionate & friendly.
I am very happy with the care I am receiving.
Dr. Neal is the best!!
May our Almighty God continue to bless Dr. Neal so he can continue helping people that are sick like me. Thank you Dr. Neal. We love you!! You're the best!!
Dr. Neal was outstanding; caring, easy to understand, detailed explanations; took time to explain everything - never felt rushed, and even gave a departing hug to me and my family. I have a high degree of confidence in him.
Dr. Neal is excellent!
Dr. Neal & Judy are the greatest! Always friendly, personable, & explain any information in understandable language.
Welcoming - Clear speaking, positive feedback, good listener, positive thinker, friendly natured, thorough reviews -
I would recommend my care providers and Stanford to everyone. Everyone I talked to told me I'm right where I need to be at Stanford for my medical issues.
Dr. Neal is the best!!!
Dr. Neal and staff is wonderful, wonderful, wonderful.
I have sent many to Stanford, you the best. Out of the ball park.
Excellent.
Dr. Neal is very busy and often runs late. He is, however, excellent.
The doctor is very kind, he made me feel much confidence.
Dr. Neal is outstanding & I understand how busy he is.
Dr. Neal & his future staff are extremely knowledgeable; professional; pleasant and courteous. Although I have a serious lung caner, my question's were all answered & future direction now much cleaner.
Wonderful, wonderful, wonderful, I can't say enough good things about Dr. Neal, and he and staff are a 10 in my book.
Compared to Kaiser, Dr. Neal was much more informed., Had much better communication skills. Gave better advice and had much more empathy. Gave me hope.
Dr. Neal together w/the doctors or NP he brings with him are very professional & knowledgeable.
Excellent professional visit!
He addressed my personal concerns, locations & explicit questions completely clearly.
The most professional & sincere doctor I have ever met. Dr. Neal focus on customer satisfaction is world class.
My mom (patient) loves Dr. Neal and Dr. Judy, NP. She trusts them fully as they are always on top of everything, but most importantly, they are genuinely compassionate.
Dr Neal is an extremely personable and caring physician. He answered my questions, gave me answers to questions I hadn't even thought to ask. When I left 'Dr. Neal's' office I felt better than I had in a very long time.
My opinion is Dr. Neal is at the top of his field.
Professional, yet friendly and concerned.
Very detailed and comprehensive explanations.
Have been seeing Dr. Neal for 5 yrs. and have been blessed to be able to so. Excellent!
Dr. Neal and the PA were so very easy to understand and attentive. Felt so good with both of them! Thank you.
Dr Neal thank you.
This time I felt the doctor was rushed and could have been more supportive.
Dr. Neal is the best! This man saved my life! He has a good manner about him, ease of understanding and makes a person feel completely at ease.
We really appreciate Dr. Neal's help and have confidence in his expertise and treatment. Dr. Neal is awesome! Highly recommend!
Dr. Neal, Allison and Judy are all wonderful.
Need translator since patient only speaks Chinese. But, overall experience is excellent.
Provider gave words of comfort during lengthy problem.
I think they are all awesome!!
Dr. Neal is an amazing doctor. He put my worries to ease about my illness.
Very good +'s.
Dr. Neal's assistant is wonderful. She is clear & thorough and VERY easy to talk to.
Dr. Joel Neal, Dr. Jody Chuang, and NP Judy Pagtama are wonderful!
All of them are very friendly, kind and professional. I love them.
Good.
Dr. Pack and Dr. Neal spent a lot of time with me (and my husband) - they gave me hope and both have excellent "people skills." I ope I can participate in the medication trial!
Dr. Neal took his time to explain what needs to be done and possible treatments in the future. Highly professional doctor, intelligent and I see why my cousin strongly recommended to me.
He was great!!
Have total confidence in Dr. Neal.
A very impressive MD, PhD.
Dr. Neal was straightforward and to the point. I appreciated all the information he provided. I highly recommend him to anyone needing this type of specialist.
Doctor Neal, Joel is great and he took care of me very well.
Excellent - uplifting.
Spent a great deal of time with me and my wife.
View More Patient Reviews
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records